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INTRODUCTION AND HISTORICAL PERSPECTIVE 
Pioneers in the field of hepatic transplantation pathology 
include Kendrick Porter1. 2 and Hank FennelJ.3· 4 who, 
while working with Starzl ,S-11 laid the foundation on 
which is based much of what is written in this chapter. Im-
portant early contributions were also made by Bernard 
Portmann 12-14 and Derek Wight,IS-19 who, working with 
Sir Roy Calne,20-24 helped to provide additional land-
marks on the road map for those who would follow. More 
recent contributors to the field, who now have become too 
numerous to mention by name, have quickly come to real-
ize that the pathology of liver transplantation covers al-
most every aspect of hepatic pathology. Just about every 
disease encountered in a native liver has, or will be, seen in 
an allograft. Moreover, an allogeneic liver is susceptible to 
new diseases, such as rejection, or provides interesting 
twists to the pathology of old ones, such as viral hepatitis. 
The broadness of the subject makes it difficult to cover ad-
equately in one chapter, although Randall Lee2s and 
Derek Wight26 have done marvelous jobs! 
The following chapter is based on personal experience 
in the practice of liver transplantation pathology and a re-
view of the current literature. It is intended primarily for 
practicing histopathologists and clinically based physi-
cians, who face difficult management problems and deci-
sions daily. A discussion of the perceived role of the pa-
thologist in a hepatic transplantation program is provided 
because it is somewhat different from that of a classic sur-
gical or tumor pathologist. An overview of pathophys-
iological concepts is added to provide a conceptual 
framework that enhances our understanding of the histo-
pathological findings . A brief review of possible clinical 
presentations is provided because the final histopathologi-
cal interpretation or diagnosis is so often based on the 
clinicopathologic background. The diagnostic approaches 
to the different types of specimens, gross (if appropriate) 
and histopathologic findings, as well as their differential 
diagnoses are the main purposes of the chapter. We bope 
that the format is user-friendly and that any advice or per-
spectives given are helpful. 
ROLE OF THE PATHOLOGIST IN A LIVER 
TRANSPLANTATION PROGRAM 
The anatomical pathologist with a special interest in trans-
plantation pathobiology can be an invaluable member of a 
large solid organ allograft program. Even at smaller 
centers or follow-up care facilities, pathologists will often 
find themselves active participants in, or at the center of, 
discussions regarding liver allograft candidacy or post-
transplantation recipient care. The pathologist, therefore, 
is first and foremost a medical consultant; proficiency in 
this role requires a fundamental working knowledge of 
four basic areas. 
A detailed understanding of liver pathophysiology is 
probably the most important prerequisite qualification. It 
will enable the pathologists to diagnose correctly original 
and recurrent disease and posttransplantation allograft 
syndromes and to anticipate problems that arise as a result 
of operative procedures or therapeutic interventions. Al-
most as important is a thorough understanding of clinical 
management problems and terminology. This allows the 
consulting pathologist to communicate the histopatholo-
gical findings effectively and put them into perspective for 
patient management. Because recipients are immunosup-
pressed and thus susceptible to a wide variety of opportun-
istic infections and associated malignancies, recognition 
of hepatic and systemic manifestations of bacterial, fun-
gal, and viral infections and the varied presentations of 
virus-associated malignancies is certainly helpful. Last, fa-
miliarity with immunopathology comes in handy when 
conducting and interpreting various immunobiological 
tests that measure effector mechanisms of allograft dam-
age, such as immunofluorescent staining, crossmatcb test-
ing, and functional analysis oflymphocytes, including the 
mixed lymphocyte response and cell-mediated lym-
pholysis. 
In everyday practice, the histopathologist will be asked 
to render "opinions" given a detailed clinical scenario, a 
task that some practitioners may find particularly diffi-
cult. The following is a typical example. Three weeks after 
liver transplantation, a recipient becomes septic, necessi-
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tating a dramatic lowering or even discontinuance of im-
munosuppression. Six days later, elevation ofliver injury 
test results prompts a liver biopsy to rule out or confirm 
the strong clinical suspicion of rejection. Although a 
straightforward histopathological diagnosis of rejection 
may easily be rendered, the physician asks the consulting 
pathologist, "Do you think we can let this rejection go un-
treated for another couple of days until the sepsis has com-
pletely cleared?" Answering this question requires experi-
ence with similar situations in the past and willingness to 
participate in a decision-making process in which the pa-
thologist will, at times, be proved wrong. This situation is 
foreign and, therefore, particularly uncomfortable for 
those of us who are used to pathologists' being the "final" 
checkpoint, responsible for the "correct" diagnosis. More 
than anything else, a willingness to participate in this type 
of decision-making process is what makes transplan tation 
pathology different from classic surgical or tumor pathol-
ogy. Perhaps the irreversibility of malignancy-associated 
therapy as opposed to the relative reversibility of trans-
plant-related treatment has dictated this difference. 
APPROACH TO TISSUE SPECIMENS 
Tissue triage, diagnostic considerations, and clinicopath-
ological correlation differ with the type of tissue specimen. 
The approach to each is discussed next. 
Pretransplant Biopsies and Outside Slides 
Most patients undergo hepatic replacement because of cir-
rhosis developing on a background of chronic inflamma-
tory hepatic disease. Correct identification or confirma-
tion of the original disease is most often accomplished by a 
review of consultation slides of core needle biopsies per-
formed elsewhere. Familiarity with those liver disorders 
that commonly recur after transplantation and those that 
are frequently associated with hepatocellular carcinoma 
assists in recipient selection and determining the need for 
adjuvant therapy before or after transplantation. A brief 
clinical history must accompany such slides, including 
any previous operative or surgical pathology reports. Fail-
ure to adhere to these guidelines may result in patient or 
disease misidentification and the possibility ofinappropri-
ate operations. Academic uses of the native liver disease 
data are entirely dependent on a thorough pretransplanta-
tion work-up. 
Patients with fulminant liver failure may be referred for 
transplantation without a firm diagnosis or thorough 
work-up. [n such instances, pathologists may be requested 
to evaluate frozen sections or "rapidly processed" slides, 
or both, of the native liver obtained via a transjugular 
biopsy, in which the liver is intravascularly approached 
from the superior vena cava. I I. 27. 28 The etiological and 
prognostic significance of microscopic architectural alter-
ations may then be used to assess the need for transplanta-
tion. [n some instances, knowing the pattern ofIiver injury 
associated with particular etiological agents will enable the 
pathologists to provide information regarding the poten-
tial reversibility and stage of the process. Reference to a 
standard liver pathology text for further information is 
suggested. 29 It must be stressed that the pathologist is only 
part of a patient management team that includes a hepa-
tologist, critical care and anesthesiology specialists, and a 
surgeon. The team members combine information gained 
from biopsy histopathological findings with those from 
liver injury tests and liver synthetic and cerebral function 
studies, but the recipient surgeon is ultimately responsible 
for the collation of this information and for the decision 
about and timing of transplantation. 
Native Hepatectomy Specimens 
In many centers the native hepatectomy specimen first 
becomes available for pathological evaluation during the 
early hours of the morning. Immediate tissue processing 
may on occasion be required to isolate RNA or tissue for 
measuring enzyme activity to identify the original disease 
(e.g., tyrosinemia) correctly. Although the majority ofna-
tive hepatectomy specimens undergo triage the following 
morning, prompt tissue processing may also be required at 
odd hours to fulfill research requests for fresh RNA iso-
lates or to establish cell cultures or lines from the native 
hepatectomy specimen. Such requests are best handled by 
in-house arrangements between the department of pat hol-
ogy and the investigators. 
Access to the entire liver, including hilar and perihilar 
tissues, with the opportunity to choose grossly abnormal 
regenerative nodules in cirrhotic livers for microscopic 
evaluation, will result in significant additions or changes 
to the original diagnosis in about 10% of cases. Clinically 
undetected and unsuspected hepatocellular or bile duct 
carcinomas are not uncommon. Other common changes 
include the discovery of structural abnormalities in the 
hilar bile ducts or their accessory glands and the detection 
of metabolic diseases that were not apparent before 
transplantation. 
Gross examination of native hepatectomy specimens 
should be done according to a predefined protocol. 30 The 
hepatic artery, bile duct, and portal vein are identified and 
opened longitudinally starting at the resection line, and 
the resection margins are sampled. Any thrombi, vegeta-
tions, calculi, strictures, fibrosis , or tumors are noted. 
Next. the hepatic veins or vena cava, if present, is identi-
fied and the resection margins are sampled. The capsular 
surface of the organ is examined for nodularity and any 
obvious defects. The gallbladder is opened and routinely 
sampled. The liver is then serially sectioned in a horizontal 
plane at I.O-cm intervals, yielding slices similar to those 
observed on a computed tomography scan. The precise 
location of any intrahepatic defect other than regenerative 
nodules (eg, tumors. cysts, and abscesses) is recorded. 
It is extremely important to slice the liver thinly (at ap-
proximately I-cm intervals) and to sample any regenera-
tive nodule that, by virtue of size or color, distinguishes 
itself from the surrounding cirrhotic parenchyma. Micro-
scopic sections other than those suspicious nodules or ob-
vious anatomical defects are taken according to a proto-
col. Routine samples should include a superficial and deep 
section of the right and left hepatic lobes; a section of the 
hepatic artery, portal vein and hepatic veins, and bile duct 
at the resection margins; and a deep hilar section. Bulk 
frozen, optimum cold-temperature compound embed-
ded. and bulk formalin-fixed tissue are saved from each 
case in an in-house tissue bank. Photographs or diagrams, 
or both, should accompany interesting or complicated 
cases. 
Failed Allografts 
~he r~asons for allograft failure differ depending on the 
tIme smce transplantation. Statistics of graft failures based 
on autopsy analysis are often difficult to interpret because 
comorbid conditions are frequently present. The majority 
of allografts fail early after transplantation because of 
"preservation" injury, vascular thrombosis, and humoral 
r~jec~onI or ~ combination of these.26• 31. 32 Acute rejec-
tIOn IS ~ relatIvely uncommon cause of early graft failure 
unless Immunosuppressive therapy was deliberately with-
drawn. Late graft failures (>4 weeks) are due to chronic 
rejection, recl;lrrent native disease (especially viral), vascu-
lar thrombosIS, or delayed manifestations of early ische-
mic preservation injury. 
The main goal of the pathological examination of allo-
graft hepatectomy specimens is precise identification of 
the cause of failure, when possible. An attempt should be 
made to correlate the pathological findings and previous 
serial biopsies with the preceding clinical course. A patho-
logical diagnosis of "widespread coagulative necrosis" 
provides little additional useful information without an 
accompanying statement or speculation of the cause. The 
sequence of the gross examination is the same as that used 
for native hepatectomy specimens.30 Particular attention, 
however, is paid to the inspection and dissection of hilar 
structures because technical problems with vascular and 
biliary anastomoses account for most allograft failures oc-
curring during the first few postoperative months. 
Microscopic sections are taken by the same protocol 
used in the native livers.30 They include sections of 
the "deep hilum," including second- and third-order 
branches of the hepatic artery, and peribiliary glands may 
be particularly informative in determining the cause of 
graft failure. Bulk frozen and formalin-fixed tissue is also 
saved in a tissue bank. 
Posttransplantation Needle Allograft Biopsies 
Posttransplantation needle allograft biopsies are the most 
common type of pathology specimens from liver allograft 
recipients and are usually obtained to determine the cause 
of graft dysfunction or to examine its status. Proper triage 
of the tissue specimen depends on the clinical differential 
diagnosis. which in turn depends on the time since trans-
plantation (Table 69 - I). Although most routine histo-
pathological studies can be completed on formalin-fixed. 
paraffin-embedded tissues. we prefer that the fresh. sterile 
tissue specimen be submitted to the pathology department 
in sterile tissue culture medium, such as RPMI 1640. An 
information sheet requesting general patient data. results 
of pertinent diagnostic tests. and clinical differential diag-
nosis is completed by the clinician at this time. The han-
dling of the specimen is based on this information (eg, 
culture for micro-organisms, and special fixation). Immu-
nofluorescence staining requires fresh-frozen tissue. 
Rarely, alternative methods of tissue preservation may be 
req uired for particular diagnostic or research purposes. 
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TABLE 69 - 1 Approximate time of onset of various syndromes 
causing allograft dysfunction after liver transplantation 
Syndrome 
"Preservation" injury 
Acute rejection 
Hepatic artery thrombosis 
Biliary obstruction or stricturing 
"Opportunistic" viral and 
fungal infection (eg, CMV, 
HSV. VZ, EBV, Candida. 
Aspergillus) 
Chronic rejection 
Recurrent or de novo viral 
hepatitis (eg. HBV. HCV. HOV) 
Recurrent nonviral 
inflammatory liver disease and 
malignancies 
Timing 
Immediate; worst during first 
week, but dysfunction may 
persist for I - 2 mo if initial 
insult is severe 
5 - 30 days; occasionally seen 
later in inadequately 
immunosuppressed patients 
0-4 wk with later increase seen 
between 18 - 36 mo (see text) 
Variable 
0-2 mo 
Usually> 60 days, but 
occasionally seen earlier 
>4-6 wk 
Usually> I yr 
CMV = cytomegalovirus; HSV = herpes simplex virus: VZ = variceUa-ws\er, 
EBV = Epstein-Barr virus: H BV = hepatitis B virus: HCV = hepatitis C virus: 
HOV = hepatitis 0 virus. 
Only slides stained with hematoxylin and eosin (H&E) are 
routine in our practice; requests for all other special stains 
or procedures are based on the H&E findings. 
Serial biopsy monitoring of recipients is particularly 
helpful in patient management, and any previous post-
transplant specimens should be reviewed with the current 
one. This not only establishes a baseline for each allograft 
but also greatly assists in the interpretation of the effect of 
therapy or disease progression. We recommend that the 
initial histological review of any of the pathology speci-
mens be performed methodically and blindly (ie, without 
a clinical history). This minimizes the introduction of 
bias, which may occur when clinical information or preju-
dices are known. However, the final interpretation must 
be based on complete clinicopathological correlation. 
BIOPSY EVALUATION OF THE DONOR LIVER 
Frozen Sections 
The pathologist may be asked to evaluate a donor liver by 
frozen section before implantation to determine its suit-
ability for transplantation.J3. 34 The requests are most 
often prompted by the macroscopic appearance of the 
organ. which raises uncertainties in the mind of the sur-
geon. In other instances. the clinical history surrounding 
the donor's death may prompt suspicion. 
Gross inspection of the donor liver by the pathologist is 
helpful, and if possible, the pathologist should assist in 
choosing the biopsy site. A 1.0-cm2 wedge or 2.0-cm long 
needle core from the anterior inferior edge of the liver is 
684 I Pathology of Liver Transplantation 
adequate in most cases when the anticipated changes are 
diffuse. The decision to perform direct biopsy sampling of 
localized defects is intuitive. 
Donor diseases identified on frozen section of the donor 
liver at Pittsburgh have included metastatic carcinoma, 
nodular regenerative hyperplasia, focal nodular hyperpla-
sia (Fig 69 - I), hepatic granulomas, severe steatosis, prob-
able alcohol injury, small subcapsular infarcts, and sub-
capsular scars. An operation may even be aborted because 
of frozen section findings, but this is uncommon. Trans-
plantation is currently contraindicated when a malignant 
tumor or severe macrovesicular steatosis33- 37 is detected. 
The severity of steatosis is roughly estimated on review 
of the H&E-stained slides; in our experience, fat stains are 
not necessary. The cutoff for disqualifying livers at the 
University of Pittsburgh is greater than 50% macrovesicu-
lar steatosis, depending on the recipient circumstances 
(Fig 69 - 2). It is clear, however, that liver allografts with 
less severe macrovesicular steatosis are also susceptible 
to an increased incidence of dysfunction after trans-
plantation.33-37 An animal model has been developed to 
study the increased vulnerability of the fatty liver to both 
warm and cold ischemic insults. 38 Microvesicular stea-
tosis. on the other hand, is often found after a short period 
of warm ischemia or other insults, and in our experience 
usually does not adversely affect the clinical course after 
transplantation. In the absence of obvious contraindica-
tions or severe ischemic injury, the pathologist is unable to 
predict the adequacy of organ function after transplanta-
tion on the basis of frozen-section light microscopic evalu-
ation before the operation. 
"Backtable" Biopsies 
In the absence of gross abnormalities, donor organs usu-
ally undergo biopsy on the backtable before implantation 
and are routinely processed for viewing the next day.39 
Figure 69 -1 Frozen section of a donor liver. This needle biopsy 
from a 2.0-<:m focal nodular hyperplasia lesion was found immediately 
subjacent to the capsular surface of the right lobe of a donor liver. 
The remainder of the liver was normal. Note the appearance of focal 
cirTtlosiS, and the large fibrous scar, containing proliferating bile 
ductules. The lesion was resected on the bacl<tabie, and the organ 
was used for transplantation without incident. 
Figure 69-2 Frozen sectlon of donor liver with severe steatosis, 
This needle biopsy shows about 60% macrovesicular steatosis, 
which, in our opinion, renders the organ suboptimal for transplantation. 
These samples provide a baseline for each organ with 
which any future alterations can be compared, Rarely, an 
unrecognized donor disease may slip past all of the fail-
safe points before implantation only to be detected after 
the organ has been placed into the recipient; aI-antitryp-
sin deficiency30 and low-grade chronic hepatitis have been 
detected in this manner. 
CAUSES OF GRAFT DYSFUNCTION 
AFTER TRANSPLANTATION 
Preservation Injury and Primary Dysfunction 
Preservation injury refers to a variety of insults resulting in 
allograft dysfunction that begin immediately after trans-
plantation and are not readily explainable on the basis of a 
technical or vascular insult. such as arterial or venous 
thrombosis. alloim munological reaction, and infec-
tion.3D, 39-43 The term. as used by the author, includes 
damage to an organ because of donor disease or insults 
arising during the agonal stages in the donor from hypo-
tension, drugs, infections. or toxins; damage to the organ 
during the harvesting process, cold preservation, and im-
plantation in the recipient; and damage incurred during or 
shortly after reperfusion,30, 39-43 Experimental animal re-
search has primarily focused on the injury that occurs 
during cold preservation, but investigators in this field 
have acknowledged that many donor and recipient factors 
contribute to poor early posttransplantation allograft 
function,39, 44, 4~ 
Pathophysiology. Clinical and experimental animal 
studies show that one of the most significant insults occurs 
during "cold preservation." when the donor organ is 
stored in a physiologically compatible preservation solu-
tion,39. 44, 46, 47 Loss of sinusoidal endothelial attachment 
to the underlying extracellular matrix results in exposure 
of underlying ground substances and. thus, loss of the nor-
mal antithrombogenic milieu. 39. 44, 46, 47 Vascular reanas-
tomosis and the reintroduction of blood then result in 
"reperfusion injury," when platelet aggregation and neu-
• 
Figure 69-3 Perioperative biopsies. A. Backtable biopsy obtained 
atter harvesting of the donor liver and infusion of preservation 
solution but before implantation into the recipient. Note the intact 
architecture and normal-appearing lobule. B. The postreperfusion 
biopsy is obtained atter vascular reanastomosis is complete and 
before abdominal closure. Note the focal neutrophilic inflammation 
(arrows). 
trophil sludging occur in the areas of denudation (Fig 69-
3). Microvascular thrombosis and localized activation of 
neutrophils with release of oxidative enzymes act together 
to diminish blood flow and prevent adequate reoxygena-
tion of the starved tissues. 39, 44, 46. 47 Kupffer cells can also 
play an important role in exacerbating preservation injury 
through secretion of toxic cytokines and other metabolic 
substances that directly affect hepatocellular function. 39 
Kupffer cells can, under other circumstances such as im-
munological injury, protect the liver and recipient from 
injury4U-~P by ingesting and clearing platelet aggregates. 
activated coagulation proteins. and immune complexesK~4 
Warm ischemia. if kept to less than 45 minutes. is usually 
minimized as a clinical problem, and the insult is primar-
ily hepatocellular and mostly reversible. It manifests mor-
phologicallyas microvesicular steatosis. often prevalent in 
periportal hepatocytes. Donor livers with pre-existing 
steatosis show an increased susceptibility to both warm 
and cold ischemic injury,38, ~~ 
Unfortunately, routine light microscopic examination 
by frozen section or even after formalin fixation and paraf-
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fin embedding cannot be used before implantation to 
identify severely damaged grafts.39 Perfusion fixation and 
electron microscopy are required for proper evaluation of 
the sinusoidal microvasculature.39.46 
Clinical Presentation. The most reliable early signs of 
allograft dysfunction are poor bile production and persist-
ent elevation of serum lactate after complete revasculari-
zation. J I A marked elevation of serum transaminases to 
levels greater than 1500 IU Iml is usual during the first few 
days after transplantation, and this is followed by a rapid 
normalization of the transaminases but a gradual rise of 
bilirubin level over the first week.3O• 39-43 Hepatic syn-
thetic function is usually preserved unless the damage is 
severe and the allograft is in danger of failure. In general, 
the trend after transplantation is toward improvement, 
unless another insult supervenes, but resolution of the 
syndrome and return of bilirubin values to normal levels 
may take several months, particularly if the initial damage 
was severe. 3O• 39 43 The decision to await the return of nor-
mal liver function after a prolonged hospital stay, often 
punctuated by other comorbid conditions, or to proceed 
with retransplantation is one of the most difficult in pa-
tient management. 
Reperfusion ofa donor liver with pre-existing macrove-
sicular steatosis results in a characteristic intraoperative 
syndrome manifest as wound site bleeding and "oozing" 
from disrupted vessels, which makes it difficult to achieve 
hemostasis before abdominal closure. 34 - 36 Marked eleva-
tions of liver injury test results immediately after trans-
plantation and early allograft dysfunction manifest as hy-
perbilirubinemia are also frequent findings. Recovery of 
recipients who were critically ill (United Network for 
Organ Sharing statuses III and IV) before transplantation 
seems to be more complicated and protracted when they 
receive a fatty liver allograft. 
Histopathological Findings. Routine histopathological 
fIndings in biopsy specimens taken within hours of com-
plete revascularization (ie, "reperfusion" biopsies) can, 
with reasonable accuracy, predict poor allograft function 
during the first few postoperative weeks. 39 Indicators of 
severe preservation injury in reperfusion biopsies include 
zonal or confluent coagulative necrosis. particularly if 
it is periportal or bridging, and severe neutrophilic 
exudation. 3O• 39-43 It must be emphasized however, that 
the subcapsular parenchyma is most susceptible to dam-
age in the perioperative periodK~S A needle biopsy speci-
men taken from this area may show more severe damage 
than that in the deeper parenchymaK~S In addition, neu-
trophilia without necrosis can be seen because of manipu-
lation of the liver alone. Therefore. as with any histopath-
ological finding, final interpretation should consider the 
complete clinical profile. 
Unless the liver is totally necrotic. the histopathological 
changes just described attributed to "ischemic" injury 
overlap with those of a regenerative response, which 
begins within 2 to 3 days. Usually, the regenerative re-
sponse is in proportion to the severity of injury. Histo-
pathological changes of less severe hepatocellular ische-
mic injury that is usually reversible include microvesicular 
ste~ltosis and hepatocellular cytoaggregation (ie, rounding 
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up of hepatocyte cytoplasm with detachment from adja-
cent hepatocytes).JO, 39-43 If the initial damage is mild, re-
generation is limited to hepatocellular mitosis, twinning of 
the plates, and nuclear enlargement. As the liver repairs 
from this mild insult, mild centrilobular hepatocellular 
swelling and bepatocanalicular cholestasis (Fig 69 - 4) are 
frequent findings,JO. 39-43 
If the necrosis is more severe but centrilobularly con-
fined and the reticulin architecture is intact, regeneration 
by hepatocellular mitosis proceeds rapidly, and restora-
tion of the normal architecture is orderly and complete. If, 
however, there is marked periportal or bridging necrosis 
with architectural collapse, cholangiolar proliferation oc-
curs, which often results in periportal fibrosisJO, 39-43; this 
may bridge between the triads and be accompanied by 
mild neutrophilic, lymphocytic, and plasmacytic portal 
inflammation (Fig 69 - 5), Centrilobular hepatocellular 
swelling and hepatocanalicular and cholangiolar chole-
stasis are typical lobular findings. JO, 39-43 With severe in-
jury, the cholangiolar proliferation and fibrosis can take I 
to 2 months or more to resolve, but they eventually disap-
pear if the liver recovers (unpublished observation). The 
appearance of blastic lymphocytes and eosinophils in the 
portal triads should arouse a suspicion of acute rejection. 
Figure 69-4 A. Mild preservatiOfl injury is characterized by 
cenlrilobular hepatocetlular swelling, hepatocanalicular cholestasis, 
and mild mixed portal inflammation without portal or central venulitis 
or bile duct damage (PT = portal tract). B. Higher magnification 
shows the details of the mild mixed portal inflammation. 
Figure 69-5 Severe preservation injury is characterized by portal 
expansion because of cholangiolar proliferation, mild mixed portal 
inflammation. and diffuse hepatocanalicular and cholangiolar 
cholestasis. The inset shows a higher magnification of a large portal 
tract illustrating the cholangiolar cholestasis (arrows) and mild mixed 
portal inflammation. 
Reperfusion of a donor liver with pre-existing macrove-
sicular steatosis results in lysis of some of the fat-contain-
ing hepatocytes. Release of the lipid into the sinusoids 
causes coalescence of the miscible fat globules, around 
which fibrin, neutrophils, and red cell congestion accu-
mulate (Fig 69 - 6). The term lipopeliosis has been used to 
describe this lesion. 37 Complete resolution of the large fat 
globules may take several weeks. 
Differential Diagnosis. Once vascular patency has been 
confirmed. the clinical and pathological differential diag-
noses include sepsis. humoral rejection, and superim-
posed acute rejection .30. 39-43 Separating sepsis from pres-
ervation injury using histopathology alone is frequently 
impossible. Humoral rejection is also difficult to separate 
from preservation injury because the pathophysiological 
mechanisms of injury are similar to each other as well 
as to eclampsia and disseminated intravascular coagula-
tion.38 - 61 Sinusoidal thrombosis with or without arterial 
spasm is the common pathway of injury with all of these 
insults, but cold storage initiates the damage in preserva-
tion injury, whereas antidonor antibodies precipitate the 
injury in humoral rejection. In addition. gradual architec-
tural repair with return of good function usually occurs 
with the former. whereas both the damage and dysfunc-
tion are likely to worsen with the latter. particularly with-
out augmentation of immunosuppression. The clinical 
history (eg, presence of preformed antibodies and length 
of preservation time) and the results of immunofluores-
cent stains of the liver biopsy provide other information 
useful in separating these two entities (see under Humoral 
Rejection). Superimposed acute rejection is identified by 
using the same histopathological criteria for acute rejec-
tion in a liver allograft not also damaged by preservation 
injury. Mild to moderate mixed portal infiltrate contain-
ing blastic lymphocytes and eosinophils with infiltration 
and damage to bile ducts and portal and central veins are 
the most useful distinguishing features of superimposed 
acute rejection. 
Vascular Thrombosis 
Unfortunately, arterial thrombosis is relatively common 
after transplantation and is a major cause of allograft dys-
function and early failure. II. 62 Portal vein and vena cava 
thrombosis are uncommon. I I. 62 Arterial defects, such as 
intimal flaps or irregularities. iatrogenically induced acute 
angle branchings or kinks, intimal or medial tears and dra-
matic reductions in caliber across a suture line, introduced 
during surgical manipulation and reconstruction of the 
vasculature, directly cause or predispose to thrombosis.62 
Any physiological insult that decreases hepatic arterial 
flow or raises intrahepatic vascular resistance is likely to 
further increase the risk of thrombosis at these sites. Arte-
rial interposition grafts, often kept in cold storage in cul-
ture medium, are another unrecognized risk factor for ar-
terial thrombosis, particularly if the wall is nonviable 
before implantation (unpublished observation). The in-
creased risk of hepatic artery thrombosis in children62. 63 is 
likely attributable to smaller-caliber vessels and techni-
cally more difficult vascular anastomoses. 
It is important to remember that the hepatic artery is the 
exclusive source of blood to the major hilar excretory 
ducts, intrahepatic bile ducts, hilar connective tissue, 
lymph nodes, and wall of the portal vein.64 Therefore, 
compromised arterial flow frequently leads to selective 
necrosis of these structures.3O, 31 Also, the allograft liver 
appears to be more susceptible to injury from arterial 
thrombosis than are native livers because, at least early 
after transplantation, it is devoid of the natural cascade-
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Figure 69-6 Donor liver with severe macrovesicular steatosis. A, 
Low-power view of donor liver showing severe macrovesicular 
steatosis involving about 50 to 60% of the lobule. B, A higher 
magnification of back table biopsy shows the severe macrovesicular 
steatosis. C, After reperfusion, some of the hepatocytes containing fat 
undergo lysis, releasing the fat, which forms large globules that block 
the sinusoid (so-called lipopeliosis). Notice the accumulation of red 
cells, neutrophils, and fibrin in the sinusoids near these lesions (arrows). 
type arterial collaterals that normally help to protect the 
liver from infarcts. 
Clinical Presentation. Hepatic artery thrombosis usu-
ally occurs within the first few postoperative weeks,62. 65 al-
though a second smaller peak in incidence is seen more 
than I year after transplantation (unpublished observa-
tion). Patients often present with symptoms related to the 
biliary tree, such as right upper abdominal pain or dis-
comfort, intermittent fever, bacteremia or fungemia be-
cause of severe cholangitis and intrahepatic biliary ab-
scesses, bile duct necrosis and bile peritonitis, biliary 
strictures, or obstruction. I I. 62. 65 If large areas of the liver 
are infarcted, fulminant hepatic failure can be seen, 
whereas if sufficient collaterals have developed, which is 
not uncommon in the pediatric recipient, the patient may 
be asymptomatic. Ultrasonography is most often used as a 
screening test: the diagnosis is confirmed with selective 
angiography. I I. 62, 65 
The second peak in the incidence of technically related 
arterial thrombosis alluded to previously occurs between I 
and 3 years after transplantation. In this subset of patients. 
an anastomosis that is less than perfect is thOUght to cause 
turbulent arterial flow immediately downstream to the su-
ture line. Alternatively, an arterial interposition vascular 
graft can develop fibrointimal hyperplasia more quickJy 
than the vasculature within the organ allograft. Eventu-
ally, these technically related problems culminate in accel-
erated atherosclerosis and arterial thrombosis, which 
present as biliary tract obstruction, ascending cholangitis, 
or both.3O· JI. 62. 66 Careful attention to detail by the trans-
plant surgeon during anerial reconstruction may decrease 
the frequency of this complication. 
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Portal vein thrombosis in a noncirrhotic allograft can be 
complete and result in catastrophic liver failure or can be 
partial and present with relapsing fever and miliary seed-
ing of the liver with bacteria. The common presentations 
in these recipients are ascites, encephalopathy, and vari-
ceal bleeding. As expected, cirrhotic allografts are more 
susceptible to portal vein thrombosis than are noncirrho-
tic allografts. 
Histopathological Findings. The gross pathological 
evaluation of the failed allograft with arterial compromise 
is of paramount importance.3O,31 First, identification of 
the arterial anatomy may require the assistance of the op-
erative surgeon. The precise location of the thrombus and 
any relationship to suture lines, vascular injuries, or other 
obvious defects such as intramural dissections, intralumi-
nal mural flaps, and mycotic aneurysms should be noted. 
Necrosis of hilar structures, especially the bile duct wall 
with bile leakage into the hilar connective tissue and su-
perimposed bacterial and fungal infection (Fig 69- 7), is 
common. 14, 26, 28.30, 31 Varying sizes of subcapsular in-
farcts may also be present. 
Needle biopsy is often of little or no value in establishing 
the diagnosis of hepatic artery thrombosis.3O, 31, 63 The his-
tological changes are varied, and needle biopsies are sub-
ject to more sampling error than usual. A completely nor-
mal histological appearance, frank coagulative necrosis or 
marked centrilobular hepatocyte swelling, cholangiolar 
proliferation with or without bile plugs, and acute cholan-
giolitis, similar to that seen with ischemic preservation in-
jury, may be observed.3O,31 In some cases, spotty acido-
philic necrosis of hepatocytes, mimicking acute viral 
hepatitis, can also be seen. If the hilar bile ducts have be-
come necrotic or filled with sludge, needle biopsies of the 
periphery can also show changes of acute or chronic ob-
structive cholangiopathy or even resemble chronic viral 
hepatitis. When necrotic tissue is encountered, Gram's 
and Grocott's stains are recommended because these foci 
often become seeded with micro-organisms. 
Many of the areas prone to necrosis from arterial throm-
bosis are not accessible to direct visualization or needle 
biopsy sampling. An attempt to salvage an allograft by ar-
terial thrombectomy may be made during surgical explo-
ration because of the "viable" gross appearance to the 
Figure 69-7 A, Hepatic artery thrombosis frequently results in necrosis of the wall of the large bde 
ducts in the hilum of the liver. The lumen of the necrotic duct is filled with bile sludge and 
inMammation. B, The necrotic duct also contains colonies of gram-positive cocci. C, This necrotic 
arterial wall shows some inflammation. and a few fungi are evident on the hematoxylin and eosin stain 
(arrows). D. However, Grocott's stain reveals numerous branching hyphae, indicative of Aspergillus 
overgrowth. 
• • 
capsular surface. Not infrequently, a frozen section of a 
needle core from the periphery of the liver may be re-
quested to "confirm" the impression of viability. Al-
though the biopsy specimen may appear normal. the sur-
geon should be warned of the possibility of hilar necrosis 
despite the normal peripheral biopsy. 
Isolated portal vein thrombosis in a noncirrhotic allo-
graft after transplantation is uncommon in our experi-
ence. Several patients in whom this complication devel-
oped shortly after transplantation presented with liver 
failure, and the pathology showed widespread coagulative 
necrosis. In several patients presenting late after transplan-
tation, the portal vein was only partially occluded, and the 
thrombus became seeded with gram-positive bacilli from 
the gastrointestinal tract. Needle biopsies taken before al-
lograft hepatectomy in these cases revealed small miliary 
infarcts in the parenchyma associated with an intense 
neutrophilic exudate. 
Differential Diagnosis. As mentioned, needle biopsy 
evaluation is usually oflittle or no value in establishing the 
diagnosis of hepatic arterial thrombosis. Therefore, in this 
circumstance. the biopsy may be more useful as a way to 
exclude other causes of dysfunction, such as viral hepatitis 
and acute rejection. The histopathological differential 
diagnosis for hepatic artery thrombosis is extensive be-
cause, in our experience, artery thrombosis can mimic al-
most every histopathological syndrome associated with 
graft dysfunction. Many times, the biopsy specimen is rel-
atively unremarkable either because vascular collaterals 
have developed and the thrombosis is inconsequential or 
because there has been necrosis of hilar bile ducts and 
changes secondary to biliary sludging have not yet devel-
oped in the periphery. When peripheral ischemic injury is 
seen. it can take the form of coagulative necrosis or centri-
lobular hepatocellular swelling and cholangiolar prolifera-
tion resembling preservation injury. Review of previous 
biopsies is usually helpful in distinguishing between pres-
ervation injury and arterial thrombosis. 
Late after transplantation, hepatic artery thrombosis or 
stenosis often presents with biliary tract obstruction or 
stricturing. 3O• 31. 62. 66 In such cases, needle biopsies may 
show changes of acute or chronic obstructive cholangi-
opathy. Ludwig and colleagues66 coined the concise 
descriptive term ischemic cholangitis to use in this cir-
cumstance. When biliary tract disease is encountered, ex-
amination of the adequacy of hepatic arterial flow is stan-
dard practice.66 Last, changes of chronic obstructive 
cholangiopathy can mimic those of viral hepatitis. The 
presence of cholangitis rather than acute cholangiolitis 
and the presence oflobular disarray, which is seen in viral 
hepatitis but not in cholangiopathy, are useful distinguish-
ing features. Exclusion of viral pathogens by adjuvant 
testing procedures can be used to rule out viral infection. 
Bile Duct Complications 
Anastomotic breakdown, mural necrosis with subsequent 
bile leakage and abscess formations, ascending cholan-
gitis. anastomotic or intrahepatic stricturing, obstruction, 
and biliary-vascular fistulas can affect the allograft biliary 
tree.)I. 67. 68 The two most common factors underlying bil-
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iary tract complications are an iatrogenically introduced 
abnormal anatomy, which predisposes to inadequate 
drainage or inordinate reflux,69 and arterial ischemic in-
jury. Both of these problems can eventually result in me-
chanical obstruction. Lack of innervation of the donor 
duct is also a consideration. There are numerous causes of 
biliary ischemia: hepatic artery thrombosis, prolonged 
cold ischemia, preformed antidonor antibodies (anti-
major histocompatibility complex [MHC] or anti-ABO 
blood group), and unrecognized and inadvertent hepatic 
artery branch ligation. Once all other causes of biliary 
strictures have been excluded with reasonable certainty, 
the possibility of recurrent primary sclerosing cholangitis 
(PSC) should be considered70• 71 in patients who had PSC 
before transplantation. 
Clinical Presentation. The diagnosis of biliary tract 
problems is most often made on the basis of selective ele-
vation of liver injury tests such as gamma-glutamyl trans-
peptidase and alkaline phosphatase, the presence of 
clinical symptoms, and the results of biliary imaging stud-
ies.3l • 67. 68 Restoration of continuity and drainage of the 
allograft biliary system is achieved by performing a duct-
to-duct or a choledochojejunal anastomosis. The anasto-
motic site is temporarily stented using a suitable-sized 
T -tube and Silastic stent, respectively. In daily clin-
ical practice, the biliary system is routinely evaluated by 
ultrasonography. T-tube cholangiograms are usually 
performed before clamping (I week) and at the time of 
T-tube removal (3 months). In patients with clinical, bio-
chemical, and ultrasonographic evidence of biliary ob-
struction, visualization of the entire biliary system is 
achieved using a T-tube cholangiogram or endoscopic ret-
rograde cholangiopancreatography (duct to duct) or per-
cutaneous transhepatic cholangiogram. During the first 2 
to 3 weeks after transplantation, anastomotic leaks or 
breakdown with bile peritonitis. mechanical obstruction. 
and bile duct necrosis caused by arterial thrombosis with 
the development of the bile cast syndrome are the most 
frequently encountered biliary complications. 
Thereafter, ready access to the biliary tree is more re-
stricted. This forces the clinical physicians to rely on other 
clinical features or diagnostic tests such as ultrasonogra-
phy and cholangiography to screen for biliary tract pa-
tency. The utility of using a needle biopsy is described 
next. 
Histopathological Findings. In general, needle biopsy 
evaluation of a liver allograft recipient for biliary tract ob-
struction or strictu ring is less useful than cholangiography 
because of a comparative insensitivity and, in some cases. 
a relative nonspecificity of histological findings. Although 
the histopathological findings seen in patients with duct 
problems are frequently classic and diagnostic, such as 
those described next. large duct obstruction or stricturing 
not infrequently will result in changes that mimic both 
acute and chronic rejection and chronic hepatitis (see dis-
cussion of differential diagnosis). 
Biliary tract complications that have been histopatho-
logically recognized include duct strictu ring. obstruction. 
acute cholangitis. periductal hemorrhage. and biliary-vas-
cular fistulas. 28. 30. 31 The features of obstruction and acute 
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cholangitis are identical to those seen in the nonallograft 
liver.29 The most important of these include a predomi-
nantly neutrophilic portal inflammatory infiltrate, peri-
ductal edema, intraepithelial and intraductal neutrophils, 
mild ductular and cholangiolar proliferation, centrilobu-
lar hepatocanalicular cholestasis, and small clusters of 
neutrophils throughout the lobules (Fig 69 - 8). 
Finally, recognition of biliary-vascular fistulas requires 
alertness to the abnormal presence of red cells in bile duct 
lumens or, conversely, bile concretions surrounded by 
foreign body giant cells in blood vessels.30 Prompt surgical 
intervention is often needed when either finding is en-
countered. Last, the presence of red cells surrounding a 
small interlobular bile duct (Fig 69 - 9) is a common find-
ing in a recipient who has just undergone transhepatic 
cholangiography.72 Resolution of this finding without 
clinical or pathological sequelae is the usual outcome. 
Differential Diagnosis. Early after transplantation, the 
distinction between biliary obstruction and cholangitis 
from acute rejection may be difficult at times, particularly 
if the patient was treated with increased immunosuppres-
sion before biopsy.73.74 An important differential diag-
nostic feature is the neutrophilic predominance of the 
portal inflammation in duct-related disorders. Acute re-
Figure 69-8 Obstructive cholangiopathy. A. Telltale 
histopathological features of bile duct obstruction or stricturing 
include portal edema (PT = portal tract). a mixed or predominanlly 
neutrophilic portal infiltrate. and cholestasis of varying severity. B. 
Higher magnification shows that mononudear inflammation may. on 
occasion. predominate in some or all of the triads and be associated 
with bile duct damage (arrow). making separation of obstructive 
cholangiopathy from late-onset acute and ear1y chronic rejection 
difficult in some cases. 
Figure 69-9 Periductal hemorrhage. Needle biopsies obtained 
shortly after cholangiographic studies can show red cells rimming the 
periphery of small bile ducts (arrows). The inset shows one of the 
affected ducts in greater detail. 
jection, on the other hand, usually shows a mixed or even a 
predominantly mononuclear infiltrate. For the first sev-
eral months after transplantation, the presence of a signifi-
cant number of eosinophils in the portal infiltrate is most 
often related to acute rejection.30, 74, 75 
Six months or more after transplantation, portal eosin-
ophilia, mild duct proliferation, and edema are more often 
the result of duct obstruction or stricturing (see later dis-
cussion) than rejection, and distinguishing between ob-
structive cholangiopathy and acute or chronic rejection 
may be particularly difficult. Changes found in obstruc-
tive cholangiopathy that can mimic rejection include a 
mixed or even predominantly mononuclear portal infil-
trate, duct damage (see Fig 69 - 8), and apparent suben-
dothelial inflammation of the portal veins. Portal fibrosis 
with mild duct proliferation, mild portal neutrophilic or 
eosinophilic inflammation, and mild centrilobular cho-
lestasis should suggest obstructive cholangiopathy. Other 
clues that biliary tract disease is masquerading as histologi-
cally classic acute rejection are (I) posttransplantation 
time of longer than 6 months and (2) presence of adequate 
immunosuppressive drug levels. 71 In addition, mononu-
clear inflammation in and around the central vein, or 
"central venulitis,"1. 2. 76. 77 can be a feature of acute or 
chronic rejection and not of duct obstruction and, there-
fore, can be helpful in distinguishing between these insults. 
Rejection 
Rejection is an immune response primarily elicited by a 
genetic disparity between the donor and the recipient. Sev-
eral different schemes are used to separate and classify re-
jection. Clinically, the time and rapidity of onset, apparent 
vigor of the reaction. and its potential for response to ther-
apy are important distinguishing features. Immunopatho-
logically, rejection can be categorized on the basis of the 
effector mechanisms responsible for tissue damage, such 
as antibody-mediated rejection, cellular rejection, or a 
combination of these two. Although all of the divisions are 
to some extent overly simplistic and artificial , the uni-
fonnity of an accepted classification scheme brings with it 
an ability to communicate more effectively. 
Recently, the World Gastroenterology Congresses 
sanctioned a group of investigators to construct a stan-
dardized nomenclature for liver allograft rejection that in-
cluded definitions, common clinical and laboratory find-
ings, and minimal histopathological criteria.7S The 
tenninology and definitions proposed by that group are 
adhered to in this chapter. 
Pathophysiology. As mentioned, rejection occurs pri-
marily because of a genetic disparity between the donor 
and the recipient, which manifests as an immunological 
reaction elicited by foreign donor antigens in the recipient. 
Various inductive, effector, and regulatory immune 
mechanisms participate in the reaction, and, as is the case 
for other immune responses, the alloresponse demon-
strates both specificity and memory.60· 79. 80 A previous 
encounter with the same antigens because of a pregnancy, 
blood transfusion, or organ transplant can result in a "pre-
sensitized" state, so that re-exposure to that same antigen 
provokes a more rapid and vigorous response. Although 
an in-depth discussion of each mechanism is beyond the 
scope of this chapter, an overview of inductive and effector 
mechanisms will assist in the interpretation of the mor-
phological manifestations of the various types of rejection . 
Several findings have led to the development of new 
concepts that have greatly enriched our understanding of 
the complex immunological events that occur during the 
initial recognition of the allograft as foreign and then later, 
when some grafts are accepted without immuno-
suppression. SI-S9 Every allograft is composed of a number 
of different cell types, including parenchymal epithelial 
cells. endothelium, smooth muscle cells, fibroblasts, and 
cells ofhematolymphoid lineage. When an organ becomes 
an allograft. the hematolymphoid cells are called "passen-
ger leukocytes" because they are carried into the recipient 
along with the organ. 90 The dendritic cell. a specialized cell 
of the monocyte-macrophage lineage, is the passenger leu-
kocyte prototype and is the most immunogenic among 
these cells.90 - 93 However. the passenger leukocyte popula-
tion in the liver also contains hematopoietic stem cells. T 
and B lymphocytes. Kupffer cells. natural killer cells, and 
conventional tissue macrophages. 
Under nonnal circumstances. hematolymphoid cells 
continuously traffic into and out of organs via hematoge-
nous and lymphatic pathways. When an organ becomes 
an allograft. complete vascular anastomosis re-establishes 
the hematogenous migratory routes that disseminate 
donor passenger leukocytes throughout the body of the re-
clpient. 76. 94 Conversely, trafficking of recipient immune 
cells into the allograft also becomes possible.76. 95 Arrival 
of the donor cells in recipient lymphoid tissues and influx 
of recipient cells into the allograft brings the two alloge-
neic hematolymphoid populations into physical con-
tact. 76. 94. 95 This results in the spontaneous fonnation of 
clusters between dendritic cells and allogeneic T cells. 
Twenty-four to 48 hours later. the lymphocytes within 
these clusters become activated. undergo blastogenesis. 
secrete a plethora of cytokines. and begin to proliferate.76 
The reaction just described represents one of the earliest 
phases of the rejection response. In the recipient lymphoid 
Pathology of Uver Transplantation I 691 
tissues, it is known as "central" sensitization.76. 94. 9S In the 
allograft, it is known as "peripheral" sensitization and is 
histopathologically recognized in needle biopsies as acute 
rejection. Most of the time, especially in liver allografts, 
acute rejection promptly responds to increased immuno-
suppression. 
Until recently, it was thOUght that the donor passenger 
leukocytes that had emigrated into the recipient were rap-
idly destroyed or simply died out within days or weeks 
after transplantation. However, we, and now others,96-98 
have conclusively shown that the donor cells can persist in 
the recipient for decades.81 - 89 
In experimental animal studies, the persistent donor 
cells are multilineage, and they preferentially home to the 
same physioanatomical destinations as their phenotypi-
cally identical recipient counterparts.87. 99 We have, there-
fore, hypothesized that a small and mobile donor immune 
system has integrated into the overwhelmingly larger re-
cipient network.81 . 84. 88 Possible consequences of this 
transfer of donor immunocytes and immune system in-
clude graft-versus-host reactions,loo-102 amelioration of 
hematolymphoid-based metabolic diseases,8s conversion 
of ABO blood group typing from recipient to donor,lol 
and drug-free allograft acceptance.SI . S8 
Once the recipient has recognized the allograft as for-
eign through contact with dendritic and other cells. matu-
ration of helper and cytotoxic T lymphocytes, release of 
cytokines, and synthesis and secretion of antibodies di-
rected at donor antigens, the effector phase of the rejec-
tion reaction commences.60· 79. so Immunosuppression is 
aimed at blunting these effector responses. The most im-
portant targets and widely studied donor antigen systems 
in rejection are those encoded by the MHC and the major 
ABO blood group antigens, which are expressed on the 
portal microvascular. portal and central vein. and hepatic 
artery endothelium and bile ducts l03 (Table 69 - 2). Other 
vascular and tissue-specific antigen systems may also be 
involved. 
Antigen expression by a cell. however. is adynamic proc-
ess. influenced by many factors (eg, drugs, lymphokines). 
For example. after transplantation. bile ducts can express 
class II MHC antigens when perturbed by any type of 
inflammation,104-I06 and class I antigen expression is in-
creased on hepatocytes l07 as opposed to nonnal. non-
transplanted livers. Although several changes have been 
detected in the expression of MHC antigens in the liver in 
association with certain graft syndromes. none to date ap-
pears to be entirely specific or clinically useful. 26. 104-106. lOS 
The liver also shows some unique properties in trans-
plantation immunobiology. For example. experimental 
porcine and murine liver allografts are accepted without 
using any immunosuppression and induce a state of 
hyporesponsiveness to other tissue from the same 
donor.6. 20. 21. 23. 99. 109 - 119 Thus. a state of "donor-specific 
tolerance" can be induced in animals by liver aJ\ografting. 
Moreover. both rat and human liver allografts have been 
shown to be relatively resistant to humoral rejection and 
are able to "protect" other nonhepatic allografts from 
the same donor from both humoral and acute 
rejection .6. 20. 21.23. 49-SI . 99.110-120 Although no spontane-
ous long-term liver allograft survival is seen in the dog, ba-
boon. rhesus monkey, or human. immunosuppressive 
--------------------------------------------------------- -
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TABLE 69 - 2 Distribution of major histocompatibility complex and ABH antigens in nonnal human IIver'03 
Sinusoidal Arteriovenous Capillary Dendritic 
Cells Antigen 
AB 
H 
HLA-A, -B 
HLA-DR 
HLA-DQ 
HLA-DP 
Hepatocytes 
+/-
Bile Ducts 
+ 
++ 
+++ 
Cells 
+ 
+ 
+ 
++ 
++ 
++ 
Endothelium 
+++ 
+++ 
++ 
Endothelium 
++ 
+++ 
++ 
++ 
+ 
++ 
++ 
+ 
HLA = human leukocyte antigen; - = negative; +- = expressed very weakly; + = expressed weakly; ++ = moderate expression; +++ = strong expression. 
From Rouger PH, Poupon R, Gane P, et aI. Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens 27:78-86, 1986. 
©1986 Munksgaard International Publishers Ltd., Copenhagen, Denmark. 
drug requirements to prevent rejection are usually less 
than those required for kidney or heart allografts in the 
same recipients. Several groups have even documented 
"spontaneous reversal" of acute rejection in human liver 
allograft recipients without bolstered immunosuppressive 
therapy.)O, 121 Moreover, the liver seems to be resistant to 
chronic rejection89, 122, 123 as compared with kidney or 
heart allografts, 
Several hypotheses have been presented to explain the 
immunological privilege of the liver allograft or so-called 
liver-induced toleranceP, 116, 124, l2S One of the most 
widely quoted has been the release of soluble class I MHC 
antigens by the donor hepatocytes, which renders the re-
cipient immune system anergic, combined with clonal de-
letion of cytotoxic effector cells within the allo-
graft.2), 116,124, l2S However, studies by Qian et a199. 126 and 
Dahmen et al,127 showing liver allograft acceptance in the 
absence of class I mismatching and without evidence of 
clonal deletion. respectively, are not supportive of that 
viewpoint. 
We have proposed a more general hypothesis based on 
the discovery that donor hematolymphoid cells can persist 
in the recipient after transplantationY, 82, 84, U~I 88,128 
Rather than representing a specific phenomenon, the liver 
simply uncovers a general process whereby donor hema-
tolymphoid cells from the allograft transfer the abili ty to 
the recipient to view the organ as "self," In essence. our 
hypothesis suggests that solid organ transplantation repre-
sents the transfer of two donor organ systems from the 
donor to the recipient.81 . 82. 84, U~I 88, 128 The first system is 
provided by the physiological functions of the trans-
planted organ, or liver. that assimilates with the gastroin-
testinal system of the recipient. The second is embodied in 
the mobile donor hematolymphoid cells that disseminate 
:lnd integrate with the overwhelmingly larger recipient 
immune system, Once integrated. the mobile donor he-
matolymphoid cells have access to immunologically pri vi-
leged sites such as the thymusY,99, 128. 129 and through 
stimulation. over time they alter the emergent properties 
of the recipient immune network, This hypothesis also ex-
plains the ability of a donor liver to change the recipient 
blood type after transplantation. 101 the susceptibility to 
graft-versus-host disease (GVHD),100-102 the transfer of 
delayed-type hypersensitivity responses, and, possibly, the 
ability to withdraw immunosuppressive therapy81-
U~K 130, 1)1 and a lesser susceptibility to chronic rejection in 
liver allograft recipients,71, 89 Further details are provided 
in Chapter 27. 
Humoral Rejection 
Antidonor antibodies can be present in the recipient be-
fore transplantation (ie, preformed) or can develop after-
ward in response to the allograft (reviewed by Demetris et 
aI61 ). They can cause failure of, enhance the survival of, or 
have no effect on the function of an allograft. 61 The conse-
quences of antidonor antibodies depend on the class, titer. 
timing of the antibody response, and the density and dis-
tribution of target antigens in the organ.61 , 1)2 Only those 
capable of causing damage are covered here. 
Historically, it had been difficult to incriminate anti-
bodies as mediators of allograft damage in liver 
transplantation . I, 2, )0. I FF-fg~ This was largely attributable 
to a well-documented resistance of the liver to humoral re-
jection in comparison with the case with kidney or heart 
allografts. I. 2. )0. 49-~fI 120. 132- m In addition. many of the 
nonimmunological complications. such as preservation 
injury and sepsis, that affect early liver allograft function 
can also produce a clinicopathological syndrome similar 
to humoral rejection. I I Moreover. comparatively poor 
survival rates after liver transplantation made it difficult to 
separate out those who died or required retransplantation 
because of antibody-mediated injury" I It is now clear. 
however. that the resistance of the Ii ver to antibody-me-
diated damage is not insurmountable. In fact, antibodies 
directed against the major ABO blood group anti-
gens~UK 136-138 and MHC antigens 139- 146 have been clearly 
shown to cause graft failure. 
The first system to be described that predictably resulted 
in humoral hepatic allograft rejection is encountered 
when ABO blood group barriers are violatedK~UK 136- 138 
Since recognizing this potentially catastrophic form of in-
jury, violating the ABO blood group barriers in liver trans-
plantation is generally avoided. and humoral rejection re-
sulting from a major blood group incompatibility is rare. 
However. in candidates with fulminant hepatic failure. in 
-whom the need is urgent, or in children for whom the 
donor pool is limited, preconditioning of an ABO-incom-
patible recipient with splenectomy, cytoreductive ther-
apy, and plasmapheresis, or a combination of these, has 
yielded acceptable results in some hands. 147 
More recently, the penalty of ignoring preformed lym-
phocytotoxic antibodies detectable with conventional 
crossmatching techniques has been defined.142-146 Al-
though they are clearly less destructive than the isoagglu-
tinins, their potential to cause allograft damage and failure 
has been recognized, even though they do not usually pre-
cipitate hyperacute rejection.142-146. 148 However, not all 
centers do report an increased incidence of early compLi-
cations in crossmatch-positive recipients. I48• 149 
Pathophysiology. Antibodies directed at antigens ex-
pressed on the vascular endothelium are the more worri-
some and can be particularly destructive because vascular 
injury interferes with the blood supply.61 Included are an-
tibodies reactive with the major ABO blood group anti-
gens and class I MHC antigens, which are detectable in 
conventional blood typing and lymphocytotoxic cross-
match tests, respectfully. Less well-defined antigen sys-
tems, such as those shared by endothelial cells and mono-
cyte-macrophages and minor blood group antigens, have 
been associated with non liver allograft injury. In xeno-
transplantation, polysaccharide antigens on the surface of 
endothelial cells are a major barrier to successful en-
graftment. 1.50-1.53 
The pathophysiology of the effector phases of humoral 
rejection have been well worked out. Antibody binding to 
the endothelium results in complement fixation, endothe-
lial damage, the formation of platelet thrombi, initiation 
of the clotting cascade, subsequent microvascular throm-
bosis, and arterial vasospasm, all of which act in concert to 
ruin the microvasculature and impair blood flow, causing 
hemorrhagic necrosis. The well-known resistance of the 
liver to humoral rejection could be the result of several 
factors: secretion of soluble MHC class I antigens by the 
liver: Kupffer cell phagocytosis of immune complexes and 
acti vated platelet aggregates; the dual hepatic blood supply 
through the hepatic artery and portal veins; and the 
unique hepatic sinusoidal microvasculature, which is de-
void of a conventional basement membrane (see Demetris 
et a 160. 61). The importance of Kupffer cells in offering pro-
tection from humoral rejection and in the shielding of ex-
trahepatic organs from injury was shown by Gugenheim et 
a1. 48. 49 Houssin et a 1..50 . .51 and Orosz et al..52 
More recently, observations in hepatic xenotransplan-
tat ion have offered yet another explanation for resistance 
of the liver to humoral rejection. ISO. 1.14 If the target cell and 
complement are from the same source (donor versus re-
cipient species), complement-mediated lysis of the target 
is less effective. Therefore, by providing its own source of 
complement. a liver allograft may protect its own endo-
thelial cells from complement-mediated lysis triggered by 
the preformed antibodies. 1.50. 1.14 Whether this form of pro-
tection is operable in allografts has yet to be determined. 
However, despite all of the protective mechanisms that 
exist. Knectle et a1 IS.5 and Gubernatis et a1 156 clearly 
showed in animals that they could be overridden by in-
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tense presensitization. As mentioned, the same was shown 
in clinical liver transplantation for ABO-incompatible 
organs and, more recently, for lymphocytotoxic anti-
bodies. 
Clinical Presentation. The syndrome that develops in 
unconditioned recipients of ABO-incompatible organs is 
the liver equivalent of "hyperacute" renal rejection, but it 
usually develops more slowly over a period of hours to 
days rather than minutes to hours.S8 . .19.137. 138. 1.17 The first 
signs of serious injury or impending doom can develop in 
the operating room after vascular reanastomosis and be-
fore abdominal closure. The liver can initially reperfuse 
uniformly and produce bile but then becomes hard and 
swollen before bile flow slows or stops altogether. Diffi-
culty in achieving hemostasis and an inordinate need for 
platelets and blood component replacement therapy sig-
nal the initiation of an intrahepatic consumptive coagu-
lopathy. Rarely are the intraoperative events serious 
enough to abort the procedure or undertake immediate 
retransplantation. However, a relentless rise in liver injury 
test results during the first several days after transplanta-
tion and other signs of impending hepatic failure signal the 
possibility that humoral rejection is occurring. 58. 59. \38. 1.17 
Hepatic angiography used to rule out arterial thrombo-
sis may show segmental narrowing, or a "sausage-link" 
appearance. 58 . .19. 138. 140, I.l7 Diffuse luminal narrowing 
with poor peripheral filling early after transplantation is 
also suggestive of immunologically mediated arterial 
vasospasm. Unfortunately, with ABO-incompatible 
organs, the marked rise in transaminase levels is followed, 
in 60% to 70% of untreated cases, by synthetic function 
failure, subsequent wound site bleeding, and other sys-
temic signs of hepatic failure that necessitate retrans-
plantation.58,59, 138. 140, 1.17 
Lymphocytotoxic antibodies can cause a spectrum of 
clinicopathological syndromes, although, in general. 
they cause less senous injury than do the isoag-
g1utinins. 1J9 - 146. 158 The variability appears to be related 
to the antibody titer, specificity, and class,n 132. 158 with 
the immunoglobulin (IgG) class being the most de-
structive.139-146. 158 Patients with low-titer IgG anti-
MHC antibodies detected on the routine crossmatch usu-
ally have no adverse consequences, but recipients with 
high-titer (especially greater than I: 500) preformed 
IgG lymphocytotoxic antibodies before transplanta-
tion 142. 144, 145 often encounter significant difficulties dur-
ing and after the operation. s3. 132. 158 However, this risk 
should be kept in perspective. The rate of crossmatch posi-
tivity is in the range of 8 to 12% of all recipients and only 
30% of those with crossmatch positivity have relatively 
high titers. Thus, the patient population at greatest risk is 
small,142. 14.1. 158. 159 and humoral rejection may be over-
looked as a cause of dysfunction or failure if it is encoun-
tered only once or twice per year. 
In those in whom problemsdodevelop, an increased in-
traoperative need for platelets has been described. 16O In 
rare cases, precipitous hemorrhagic necrosis similar to 
that seen with isoaggiutinins can occur. More frequently, a 
persistent rise in serum bilirubin level during the first week 
after transplantation, accompanied by refractory throm-
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bocytopenia, low complement activity, and a biopsy 
showing changes of "preservation" injury, is the charac-
teristic scenario. This is usually followed by the onset of 
acute (cellular) rejection and the need for increased immu-
nosuppression.s3, 132, 146 Ischemic biliary necrosis later 
manifested as biliary sludge, obstructive cholangiopathy, 
and small bile duct loss are other serious late manifes-
tations. S3, 132, 146. 161, 162 
Histopathological Findings. The histopathological find-
ings depend on the timing of the biopsy and the nature of 
the presensitized state. For ABO-incompatible organs, 
samples taken within 2 to 6 hours after the operation show 
a clustering of neutrophils and red cell sludging in the sin-
usoids and focal platelet-fibrin thrombi in portal and cen-
tral veins. Hemorrhage into the space ofDisse, hepatocel-
lular cytoaggregation, and single-cell acidophilic necrosis 
may also be seen. SR, S9, 138, IS7 
Samples taken 1 to 2 days later begin to show clusters of 
hepatocytes undergoing coagulative necrosis, red cell con-
gestions, and hemorrhage (Fig 69-10). The areas of ne-
crosis may not show any particular lobular distribution. 
Veins often show circumferential fibrin deposition, 
whereas arteries are usually less severely affected; how-
ever, on occasion, they may show neutrophilic or necrotiz-
ing arteritis, or both. A mild neutrophilic portal exudate 
usually appears at 2 to 3 days, along with focal cholangio-
lar proliferation, the latter of which is interpreted as a sign 
of regeneration. The histological features up to this point 
are difficult to separate from those of preservation injury. 
Thereafter, progressive patchy hemorrhagic infarction of 
the organ is not unusual. S8. S9. 138. IS7 
Because the hepatic injury is generally less florid in pa-
tients harboring preformed Iymphocytotoxic antibodies, 
it is difficult to reconstruct the sequential histopathologi-
cal findings from clinical needle biopsy samples. 146 There-
fore. a clinically relevant small animal model of humoral 
rejection caused by anti -class I MHC antibodies has been 
developed .s3• 132 The time sequence of the histopathologi-
cal changes in that model is shown in Table 69-3. S3 
In clinical samples, reperfusion biopsies from patients 
with a positive lymphocytotoxic crossmatch more often 
contain platelet aggregates in the portal or central veins 
than do those from crossmatch-negative controlss3, 146 
(Fig 69 - II). In the first week after transplantation, spotty 
acidophilic necrosis of hepatocytes, centrilobular hepato-
cellular swelling accompanied by cholangiolar prolifera-
tion, and hepatocanalicular cholestasis often appear. 
Neutrophilic or necrotizing arteritis is rare. S3, 146 Overall, 
the histopathological changes closely resemble those of 
preservation injury, except for subtle arterial changes, 
which may not be present in needle biopsy samples. These 
include endothelial hypertrophy, medial thickening, and 
medial myocyte vacuolization and are best observed in the 
perihilar region of allograft hepatectomy specimens.s3, 146 
Other hilar changes in humoral rejection include conges-
tion of the peribiliary vascular plexus, partially organized 
thrombi in arterial branches, and focal mural necrosis of 
large septal bile ducts. S3, 146 
If allograft failure does not occur, superimposed acute 
(cellular) rejection usually becomes evident within 5 to 7 
days of transplantation, n, 146 at which time the diagnosis 
of rejection becomes obvious. As mentioned, long-term 
sequelae of an early humoral insult can include biliary 
sludge and stricturing with obstructive cholangiopathy, 
obliterative arteriopathy, and loss of small bile ducts or 
chronic rejection. 
The gross appearance of failed ABO-incompatible 
grafts at the time of retransplantation is similar to that of 
other organ allografts undergoing "hyperacute" rejection. 
They are often enlarged, cyanotic, and mottled with areas 
of necrosis. S8. S9 The capsule mayor may not be ruptured . 
Hepatic artery and portal vein thrombosis is variably 
present. Microscopically, one observes large geographic 
areas of hemorrhagic necrosis. Focal fibrinoid necrosis of 
arteries may be seen but is present in only a minority of 
cases. More common vascular findings include arterial 
and venous endothelial cell hypertrophy, neutrophil 
sludging, and focal fibrin deposition around a partial cir-
cumference of the vessel, with a mass of fibrin extending 
Figure 69 -1 0 Humoral rejection of an ABO-incompatible organ. A, Note the geographic areas of 
hemorrtlagic necroSIs (outlined by arrows). B, A higher magnification shows the loose fibrin thrombi in 
the portal vein (81fOW) and widespread hemormagic necrosis. 
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TABLE 69-3 Routine histopathological findings in rodent liver allograft recipients presensltized with skin graft from the same donor 
1-3 Min 10-30 Min 1-3 Hr 6-24 Hr 36-48 Hr 72-96 Hr 
Platelet plugging + ++ ++ + + + 
Endothelial hypertrophy or vacuolization + ++ ++ ++ ++ 
Hepatocyte necrosis + ++ ++ ++ 
Sinusoidal neutrophilia + ++ + + 
Neutrophilic portal venulitis + ++ + + 
Portal artery thickening + ++ ++ ++ 
Arterial myocyte vacuolization + ++ 
Cholangiolar proliferation (focal) + ++ 
Mononuclear inflammatory infiltrate + ++ 
Biliary sludge + 
IgG 
Sinusoids + ++ ++ + + + 
Ponal and central veins + ++ + + 
IgG = immunoglobulin G. The findings were semiquantitatively from - = not present to +++- = severe. 
From Nakamura K, Mutase N. Becich MJ, et al. Liver allograft rejection in sensitized recipients: Observations in a clinically relevant small animal model. Am J 
PathoI142:1383-1391. 1993. 
Figure 69 -11 Humoral rejection of an ABO-compatible organ. A. A 
failed allograft removed 2-3 days after transplantation from a patient 
with a strongly poSitive (titer> 1: 1 024) immunoglobulin G 
Iymphocytotoxic crossmatch shows pen portal necrosis (arrows) and 
focal neutrophilia in the areas of damage. B. A higher magnification 
shows sludging of platelets in the portal vein (arrow) endothelial eell. 
hypertrophy. and mild neutrophilic accumulation. C. A needle biopsy 
from a different patient with strong positive crossmatcn obtained 1 
week after transplantation shows central ballooning. cholestasis. and 
cholangiolar proliferation (lower left comer). changes that are difficult 
to separate from preservation injury. 
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into the lumen. 58, 59 Arterial medial thickening and myo-
cyte vacuolization are common and probably represent 
morphological manifestations of vasospasm. 
Immunofluorescent and immunoperoxidase stains in 
ABO-incompatible organs will often reveal IgM, focal 
IgG, and complement components C3, C4, and Clq in 
an occasional artery and in the sinusoids. However, de-
posits of IgG, IgM, and Clq may be seen in a similar dis-
tribution in allografts with nonimmunologically mediated 
injury, and background fluorescence is usually a con-
founding problem. Elution studies can be performed to 
confirm the identity of the deposited antibodies. 58, 59 The 
final diagnosis should be based on a complete clinicopath-
ological analysis during which other nonimmunological 
causes of graft failure are excluded, The immunofluores-
cent findings in ABO-compatible organs with humoral re-
jection are discussed next. 
Differential Diagnosis. As mentioned, humoral rejec-
tion in an ABO-incompatible organ can easily be confused 
or overlap with hemorrhagic liver necrosis precipitated by 
a severe hypotensive insult, sepsis, and vascular thrombo-
sis. 58. 59,146,163,164 Simply knowing that the organ is ABO 
incompatible and recognizing the injury described pre-
viously are often sufficient to distinguish these entities, 
provided that the organ underwent a biopsy before be-
coming totally necrotic. 
Under ABO-compatible circumstances, the presensiti-
zation state and clinical profile can provide useful infor-
mation for the interpretation of the histopathological find-
ings and vice versa. For example, a recipient who harbors 
high-titer (> I : 32 - 500) preformed IgG Iymphocytotoxic 
antidonor antibodies should be assumed to be at greater 
risk for humoral rejection compared with a recipient with 
low-titer « I : 32) antidonor antibodies, particularly when 
there is no other obvious technical cause of allograft dys-
function. 142. 145.158, 159 A diagnosis of humoral rejection is 
further supported when there is persistence of the pre-
formed antibodies after transplantation. a drop in the 
platelet count and persistent thrombocytopenia below 
50.000 mm-3. and hypocomplementemia compared with 
normal pretransplantation values. 158 
Subtle histopathological clues that humoral rejection is 
occurring include arterial endothelial cell hypertrophy, ar-
terial medial thickening, and myocyte vacuolization with 
features suggestive of parenchymal ischemia, such as cen-
trilobular hepatocellular swelling.l46 Fibrinoid necrosis 
and inflammatory arteritis are more definite features of 
humoral rejection but are rarely seen in a needle biopsy. In 
addition. the cholangiolar proliferation, acute cholangio-
litis. centrilobular swelling, and hepatocanalicular chole-
stasis in severe preservation injury generally improve over 
time. whereas these same changes generally worsen with 
time in serial biopsies from patients with humoral rejec-
tion . Moreover. humoral rejection is usually followed by 
acute (cellular) rejection. 
In our experience. the immunofluorescence findings in 
ABO-compatible allografts are generally supportive, but 
alone they rarely are diagnostic unless the humoral rejec-
tion and immune deposits are florid. When detectable. de-
posits of IgG. C3. and C4 in the arteries and in the portal 
and hilar microvasculature. without heavy a 2-macroglo-
buLin or other macromolecule deposition, are more indic-
ative of humoral rejection than deposits ofIgM and Clq, 
which frequently become lodged in necrotic arterial walls, 
regardless of the cause of damage. 
Acute Rejection 
Acute rejection has been defined by the World Congresses 
of Gastroenterology international paneF8 as "inflamma-
tion of the allograft, elicited by a genetic disparity between 
the donor and recipient, primarily affecting interlobular 
bile ducts and vascular endothelia, including portal and 
hepatic veins and occasionally the hepatic artery and its 
branches." "Cellular rejection" is an acceptable synonym, 
because the descriptive adjective highlights the most 
prominent biopsy feature. Other synonyms that appear in 
the literature include early rejection, nonductopenic re-
jection, rejection without duct loss, and reversible rejec-
tion. The panel does not encourage use of these latter 
terms. 78 
Pathophysiology. As discussed in more detail later, the 
morphological manifestations of acute rejection can be di-
rectly related to the pathophysiological mechanisms re-
sponsible for development of the reaction. With vascular 
anastomoses restored, hematogenous migratory routes for 
passenger leukocytes are re-established, and some, but not 
all, of the donor hematolymphoid cells emigrate from the 
allograft into the tissues of the recipien t. 76, 87, 94, 128 There 
they elicit a strong proliferative immune response, also 
known as "central sensitization," that results in the for-
mation of cytotoxic T lymphocytes and the development 
of an antidonor antibody response, both of which can 
damage the organ.76, 87. 94.128 Conversely, recipient T cells 
entering the allograft spontaneously cluster with the re-
maining donor dendritic cells that are found exclusively in 
the portal triads and in the connective tissue immediately 
subjacent to terminal hepatic venules.76 These clusters re-
sult in T cell activation, blastogenesis. proliferation, and 
secretion of cytokines that upregulate MHC antigens and 
adhesion molecules on nearby vascular endothelium 165 
and act as chemotactic agents. which enhance the immi-
gration of white cells into the tissues. 76. 105. 106. 108 This re-
action is histopathologically recognized as acute rejection 
and results in the development of cytotoxic T lymphocytes 
and secretion of other chemotaxins that recruit macro-
phages and neutrophils, which in tum release oxidative 
products, leading to nonspecific damage of structures tar-
geted for injury. Targeted for injury are the portal micro-
vasculature, portal and central vein endothelium, small 
bile ducts, and arterial endothelium. Hepatocytes seem 
relatively spared from direct assault. Untreated, the endo-
thelial injury culminates in microvascular congestion. 
thrombosis. and ischemic necrosis of the organ. Fortu-
nately. however, this reaction (acute rejection) is easily re-
versible with increased immunosuppression. 
Clinical Presentation. Acute rejection usually first 
occurs between 5 and 30 days after transplantation. 
although earlier or later presentations can be seen 
in presensitized patients or in those who receive less 
than optimal baseline immunosuppression. Because 
there is little controversy regarding acute rejection and 
most groups report similar if not identical find-
ings,., 2, 12, 14-16,18,30,73,74,77, 166-17S specific bibliographic 
references to particular features are not included at each 
juncture. 
Clinical findings are often absent in early or mild acute 
rejection, although in late or severe cases fever, enlarge-
ment, cyanosis, and tenderness of the allograft frequently 
occur. Bile drainage from aT-tube often becomes thin and 
pale, and the flow is decreased. Occasionally, ascites de-
velops because of liver swelling, increased intrahepatic 
pressure, and production of lymphatic fluid.78 
Liver dysfunction is usually manifest as concomitant, 
nonselective elevations of some or all of the standard liver 
injury test findings, including total bilirubin, alanine 
aminotransferase, aspartate aminotransferase, y-g1utamyl 
transpeptidase, and alkaline phosphatase levels.78 Periph-
eral blood leukocytosis and eosinophilia are also fre-
quently present. Biochemical tests of the peripheral blood 
often show elevation of various interleukin levels or their 
receptors, neopterin, amyloid A protein, and antidonor 
class I MHC antibodies. 23, 26,60,77, 172 Unfortunately, all of 
the clinical and laboratory findings lack sensitivity or spec-
ificity. The diagnosis is suspected on clinical grounds and 
is confirmed by examination of a core needled biopsy 
specimen or a fine-needle aspirate of the allograft, the 
former of which has become the gold standard method of 
establishing the diagnosis. 
Histopathological Findings. Acute rejection is charac-
terized by (I) predominantly mononuclear but mixed 
portal inflammation containing blastic or activated lym-
phocytes, neutrophils. and eosinophils; (2) subendothelial 
inflammation of portal or terminal hepatic veins, or both; 
and (3) bile duct inflammation and damage.78 Minimal 
diagnostic criteria needed to establish the diagnosis of 
acute rejection include a least two of these histopathologi-
cal findings (mixed portal infiltrate and clearly defined 
bile duct damage) and biochemical evidence of liver dam-
age. 78 The diagnosis is strengthened if greater than 50% of 
the ducts are damaged or if unequivocal endotheliitis of 
portal or terminal hepatic vein branches can be identi-
fied. 78 As with all allografts, interference with blood flow at 
either the arterial or the microvascular level is one of the 
most serious manifestations of liver rejection. Findings 
that are associated with severe injury and used for histo-
pathological grading include lobular inflammation, cen-
trilobular necrosis, arteritis, and inflammatory bridging. 
Immunophenotypic analysis of the inflammatory cells 
present during acute rejection reveals a predominance of 
T lymphocytes. dominated by CD8+ subset in the portal 
triads and more specifically, in the damaged bile 
ducts. il~K 176-178 However. B cells. macrophages, and other 
leukocytes are also present. 103. 106. 108. 176. 179 A minority of 
cells demonstrating phenotypic characteristics of den-
dritic cells may also be seen early after transplantation. 
Expansion of the infiltrative cells in vitro using interleu-
kin-2 (IL-2) and subsequent functional analysis have dem-
onstrated the presence of activated T lymphocytes dis-
playing proliferative and cytotoxic activity directed at 
donor MHC antigens. 178. 180-1&.4 
Infiltration and damage to small bile ducts are impor-
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tant features used to recognize acute rejection and there-
fore meri t further description. The bile ducts show inflam-
matory cells inside the basement membrane, with 
evidence of damage to the epithelial cells such as paranu-
clear vacuolization, pyknosis, and cytoplasmic eosinophi-
lia. Luminal disruption with breaks in the basement 
membrane can occur, but well-formed portal-based gran-
ulomas are not generally seen. In response to the injury (or 
microenvironment), the biliary epithelium also shows en-
larged nuclei, an increased nucleus-to-cytoplasm ratio, 
nucleoli, and mitosis, 
Small portal tract arteries and arterioles are difficult to 
locate during acute rejection. Endothelial swelling and 
mural hypertrophy are most commonly observed when 
the arteries are found. Necrotizing or neutrophilic arteritis 
is rare. Lymphocytic inflammation can be seen but is a 
poorly reproducible findingl83 and is present in less than 
5% of cases. Although inflam matory arteritis may be seen 
with acute rejection, the vessels most commonly affected 
are located in the hilum and are not usually accessible by 
needle biopsy (Fig 69 - 12). Therefore, the low incidence of 
arteritis detected in needle biopsy samples is likely due to a 
sampling problem. 
As rejection worsens, the portal infiltrate may spill over 
into the periphery of the lobule, associated with periportal 
hepatocyte necrosis (Fig 69 - 13). The remainder of the 
lobule usually shows mild Kupffer cell hypertrophy, a 
slight increase in inflammatory cells in the sinusoids, and 
infiltration of the connective tissue of the surrounding 
central vein by cells, similar to that seen in the triads. 
Zonal centrilobular hepatocyte swelling, necrosis, and he-
patocanaIicular cholestasis may also be present. Signifi-
cant lobular disarray is unusual. Some of the lobular find-
ings may be related to ischemic injury occurring before or 
as a consequence of rejection. Decreased hepatic blood 
flow and disruption of the sinusoidal microvasculature. 
particularly near the central vein, 1.2. 76. 77 can also contrib-
ute to the "ischemic" lobular changes. 
Treatment of acute rejection with additional immuno-
suppression before a biopsy specimen is obtained may 
Figure 69 -12 Inflammatory arteritis associated with acute rejection. 
Lymphohistiocytic intimal inflammation of an artery (arrow) resulting 
from acute rejec1ion is rarely detec1ed in a needle biopsy unless the 
biopsy inadvertently samples a relatively large artery. as shown here. 
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Figure 69-13 Acute rejection. A. Mild acute rejection shows mild mixed portal inflammation with 
el/idence of duct damage and portal Of centrall/enulitis or endotheliitis in some but not a majority of 
the triads, B. A higher magnification shows the bile duct damage (thick arrows) and subendothelial 
inflammation (thin Brrow) of the portall/ein , C. In moderate acute rejection the mixed infiltrate inl/oll/es 
most or all of the triads. and the portal infiltrate may spill ol/er into the edge of the triads. as shown 
here, Howel/er. there is no el/idence of centrilobular necrosis. inflammation. and dropout. D. Sel/ere 
acute rejection is characterized by a usually moderate to sel/ere but I/ariable portal infiltrate associated 
with moderate to sel/ere lobular inflammation and necrosis (PT = portal tract: CV = centrall/ein), E. A 
higher magnification of a centrall/ein region shows hepatocyte dropout and inflammation, F. The failed 
allograft with sel/ere acute rejection also showed subendothelial lymphocytic inflammation of large 
hilar artenes and ear1y mild foam cell accumulation, 
make the histopathological diagnosis more difficult be-
cause of subsequent loss of the subendothelial infiltration 
of veins and a relative decrease in the number of mononu-
clear inflammatory cells.78 
Currently, several well-known systems are used for 
grading acute rejection (Table 69 - 4). All of these systems 
include mild, moderate, and severe grades, and there are 
few substantial differences between them, except for the 
Minnesota scheme, which includes bile duct loss under se-
vere acute rejection. Each of the grading systems listed in 
Table 69-4 has shown utility in terms of prognosis or pre-
diction of liver function abnormalities at the home insti-
tution. However, the National Institute for Diabetes and 
Digestive and Kidney Diseases (NIDDK) system186 has 
the additional advantage of proven reproducibility and 
prognostic value across three separate institutions and five 
separate pathologists. A challenge in the near future is to 
combine all of these schemes into one so that a common 
nomenclature and grading scale can be used. 
ChroniC Rejection 
Chronic rejection is usually refractory to immunosup-
pressive therapy and is an important cause of late graft 
failure,187-191 although it may be decreasing in inci-
dence. 187. 192 Chronic rejection has also been defined by 
the World Congresses of Gastroenterology panef18 as a 
"usually irreversible process defined by two main histo-
pathological features: obliterative vasculopathy and loss of 
bile ducts. Although these two components usually coex-
ist, they occasionally may occur independently. The proc-
ess is elicited by a genetic disparity between the donor and 
the recipient. but other cofactors may be involved." 
. , Ductopenic rejection" is considered an acceptable syn-
onym. but the panej78 discouraged the use of other names 
such as late rejection. irreversible rejection. rejection with 
duct loss. vanishing bile duct syndrome, acute vanishing 
bile duct syndrome. and chronic vascular rejection that 
appear in the literature as substitutes for chronic rejection. 
The consensus document just mentioned78 explains the 
conundrum associated with the term chronic: 
although the tenn "chronic" technically implies a time 
parameter, none is intended. Chronic rejection has been de-
scribed as early as 2 - 3 weeks after transplantation and cer-
tainly may occur after this time. although it is unusual be-
fore 60 days after transplantation. By convention. the tenn 
"chronic" has been used in other organ allografts to im-
ply Irrel'ersible changes. The alternative tenns men-
tioned ... "vanishing bile duct syndrome" and "ducto-
penic rejection" are descriptors of one of the major findings 
but loss of ducts is not a defining feature of an irreversible 
process. For the time being, by convention the tenn 
"chronic" provides a brief. understandable shorthand for a 
complex and incompletely understood process. 
Pathophysiology. Risk factors for the development of 
chronic rejection reveal possible pathogenic mechanisms 
responsible for the development of this disorder. These in-
clude multiple or poorly controlled acute rejection epi-
sodes. chronic rejection in a previous failed allograft. a 
positive pretransplantation Iymphocytotoxic crossmatch. 
anti-MHC antibodies that develop after transplantation. 
cytomegalovirus (CMV) infection. matching at the class II 
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MHC locus and mismatching at the MHC class I locus, 
nonwhite recipient race, chronic viral hepatitis, and treat-
ment with interferon-a.4• 3O, 161, 167, m, 182, 187-191, 193-201 
Most of these risk factors identify patients who either have 
been sensitized against the allograft or show strong immu-
nological reactivity toward it. Hyperlipidemia, hyperten-
sion, diabetes, and preservation injury have, to our knowl-
edge, not been associated with chronic rejection of the 
liver but are thought to contribute to the development of 
obliterative arteriopathy (OA) in other solid organ 
a1lografts.202 
The major defining feature of chronic rejection is OA, 
because bile duct loss alone can occur with several nonim-
munological or nonrejection-related disorders. Several 
groups have suggested that the pathogenic mechanisms 
involved in the development ofOA include a "response to 
immunological injury," the same hypothesis used to ex-
plain the development of atherosclerosis in the general 
populationKOMO-OM~ Thus, attempts at classification are 
based on the nature of the initial insult. In an allograft, the 
cause of the injury appears to be primarily rooted in an al-
logeneic immune response. 202 -20S Likely arterial targets of 
this response include the endothelium, periarterial den-
dritic cells, and lymphatic capillary endothelium in the 
adventitiaIOMO-OM~ because disruption of the lymphatic ves-
sels could cause mural edema and alter the intimal milieu. 
However, mUltiple other cofactors, including preservation 
injury, viral infections (especially CMV), hyperlipidemia, 
hypercholesterolemia, hypertension. and diabetes, could 
certainly contribute to the insult and exacerbate the arte-
rial disease.202 In any event, the arterial injury triggers a 
cascade of intimal inflammation, growth, and repair (ex-
plored in detail by Hayry and colleagues202) that eventu-
ally results in the characteristic OA . 
The second major target for injury in chronic rejection. 
the bile ducts, are directly susceptible to immunological 
injury from invading inflammatory cells and indirectly 
susceptible to ischemic damage because of arterial oc-
clusion and destruction of the peribiliary capillary 
plexus. 190. m. 206 Direct recognition of bile duct cells by 
activated recipient lymphocytesl80-182 and injury via the 
development of cytotoxic T lymphocytes (CTLs) are 
usually noted ultrastructurally and histopathologic-
ally4· 167. 176. 207 and are the defining features of both acute 
and chronic rejection. 78 In addition. cytokines locally re-
leased by the invading lymphocytes can either directly in-
jure the ducts or recruit neutrophils and macrophages via 
chemotaxins that indirectly cause damage through release 
of oxidative products. These same effector mechanisms. 
as well as antidonor antibodies. can also destroy the small 
portal arterioles and fine webbing of capillaries that are the 
final conduit of arterial blood to the ducts. 190. m. 206 In ad-
dition. this unique portal microvasculature can be plugged 
and ruined by platelets and neutrophils in presensitized 
patients. explaining the association between preformed 
antibodies and bile duct 10ss.I46. 161. 193 
Donaldson. O'Grady, and others l93. 19~K 198. 199 suggested 
that bile ducts can also contribute to their own destruction 
by acting as antigen-presenting cells when their class II 
MHC antigens are matched with those of the recipient and 
when they are simultaneously mismatched for class I 
MHC or infected with CMV (see under Cytomegalovirus 
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TABLE 69-4 Grading systems tor acute liver allograft rejection 
Acute 
Rejection 
Mild 
Moderate 
Severe 
NIDDK System 1". 
Rejection infiltrate 
in some but not a 
majority of the 
triads confined 
within the portal 
spaces 
Rejection infiltrate 
involving most or 
all of the triads with 
or without spillover 
into the lobule; no 
evidence of 
centrilobular 
necrosis. ballooning. 
or dropout 
Rejection infiltrate 
in some or all of the 
triads with or 
without spillover 
into the lobule with 
or without 
inflammatory 
linkage of triads; 
associated with 
moderate severe 
lobular 
inflammation and 
necrosis 
Minnesota173 
Lymphocytic or 
mixed portal 
infiltrate with 
< 50% damaged bile 
ducts and 
endotheliitis of 
portal or central 
veins 
Lymphocytic or 
mixed portal 
infiltrate. > 50% 
damaged bile ducts. 
with or without 
endotheliitis 
Acute rejection plus 
arteritis. paucity of 
bile ducts. or central 
hepatocellular 
ballooning with 
confluent dropout 
of hepatocytes 
Europeanl 72,t 
Inflammatory 
changes are 
generally mild and 
pa tchil y distri bu ted 
within portal areas; 
bile duct damage 
and venous 
endothelial 
inflammation are 
both mild 
Inflammatory 
changes are more 
severe and 
widespread. with 
the majority of 
portal tracts 
involved; bile duct 
damage and venous 
endothelial 
inflammation are 
both conspicuous 
All three classic 
features of acute 
rejection are present 
to a marked degree; 
they are sometimes 
accompanied by 
additional 
peri portal. 
sinusoidal 
parenchymal. and 
vascular changes as 
outlined in foolDote 
Williams et apia 
Minimal infiltration 
of portal tracts and 
portal vein branches 
with or without 
involvement of 
interlobular bile 
ducts combined 
with minimal 
subendothelial 
infiltration of 
central veins and 
minimal infiltration 
of the hepatic 
parenchyma about 
central veins 
More extensive 
infi.ltration of both 
portal tracts and 
parenchyma with 
focal. non bridging 
necrosis of the 
hepatic parenchyma 
Marked 
mononuclear 
infiltration of portal 
tracts and 
parenchyma with 
bridging 
hepatocellular 
necrosis 
Kemnitz et aim 
Slight mononuclear, 
predominantly 
lymphocytic, or 
partially mixed 
cellular infiltration 
of the portal tracts; 
venous endotheliitis 
in portal, central, or 
both localizations; 
degenerative 
parenchymal 
changes up to 
necrosis with 
infiltrates of up to 
10% of the hepatic 
parenchyma; bile 
duct damage 
More pronounced 
infiltration of the 
portal tracts, 
degenerative 
changes of the 
hepatic parenchyma 
and focal 
non bridging 
necroses of the 
hepatic 
parenchyma, mixed 
but predominantly 
mononuclear 
infiltration affecting 
10-30% of the 
whole hepatic 
parenchyma. portal 
and central venous 
endotheliitis. bile 
duct damage 
Marked mixed but 
predominantly 
mononuclear 
infiltration of the 
portal tracts and the 
hepatic 
parenchyma. with 
pronounced 
degenerative 
changes and 
necroses that affect 
> 30% of all 
hepatocytes and 
that are panly 
bridging; venous 
endotheliitis in 
portal and central 
localization; bile 
duct damage 
'For all grades of rejection at least two of the three histopathological findings must be present: a predominantly mononuclear infiltrate. bile duct inflammation Or 
damage. and subendotheliallocaliz.ation of mononuclear cells in the portal or central veins. 
tThe severity of (I) ponal inflammation. (2) bile duct damage. and (3) venous subendothelial infiltration are subjectively scored on a scale of 0 (none) to 3 (severe) and 
are collated to provide a final rejection grade. In some cases. other features that are inconsistently seen in acute rejection (eg, portal inflammatory spillover. sinusoidal 
endotheliitis. perivenular IDflammation with or without necrosis. and arteritis) are used to upgrade the overall severiry of acute rejection. 
:>'IDDK - National Institute of Diabetes and Digestive and Kidney Diseases. 
-
Hepatitis). In vitro, we have shown that bile duct epithe-
lium can present alloantigen to primed lymphocytes l82; 
but they are much less efficient at antigen presentation 
than are endothelial cells tested in the same assay. 182 This 
implies, but does not prove, that arterial or microvascular 
destruction may be the critical lesion in chronic rejection. 
Clinical Presentation 
Chronic rejection usually does not occur before 2 months 
after transplantation and most frequently develops (1) 
after an unresolved episode of acute rejection, (2) after 
multiple episodes of acute rejection, or (3) indolently over 
a period of months to years, with few or no clinically ap-
parent acute cellular rejection episodes.78 However, it has 
been observed as early as 2 weeks after transplanta-
tion. 77• 194 Often, unresolved or indolent rejection is appar-
ent only because of a persistent elevation of liver injury 
test findings.4. 12. 15. 18,67. 187-1111.205 If clinical symptoms 
are present, they usually resemble those of acute rejection 
until allograft dysfunction becomes severe enough to 
cause jaundice.4 , 12, 15.78.167.187-191. 205 Late findings pre-
saging allograft failure include biliary sludging or the ap-
pearance of biliary strictures, hepatic infarcts, and finally 
loss of hepatic synthetic function, which can manifest as 
coagulopathy, malnutrition, and hepatosplenomegaly.78 
Standard liver injury test abnormalities in a patient with 
chronic rejection usually show a progressive cholestatic 
pattern, with preferential elevation of y-glutamyl trans-
peptidase and alkaline phosphatase. 78 Some groups have 
found that the level of serum bilirubin and the percentage 
of portal tracts without bile ducts in a patient with chronic 
rejection may help to distinguish between those who have 
sustained irreversible damage and those who potentially 
could recover with treatment208 or spontaneously. 189. 209 
Arteriograms may be used to support the diagnosis of 
chronic rejection by showing pruning of the intrahepatic 
arteries with poor peripheral filling and segmental 
narrowing.78. 187. 188.210.211 
Histopathological Findings 
The two histopathological findings that are indicative of 
chronic rejection are loss of small «60 ,urn) bile ducts in-
volving more than 50% of the triads and OA with foam 
cells. I. 2. 4. 12. 15.78. 167. 187 - 191.205 although arteries with 
pathognomonic changes are rarely present in needle 
biopsy specimens (Fig 69-14). Cases with either isolated 
bile duct loss or foam cell arteriopathy alone may occur, 
but usually both features occur together. 26 Duct loss with-
out arteriopathy may be seen in some patients as a result of 
non - rejection-related complications (eg, bile duct stric-
tures. drug toxicity, and CMV infection), so appropriate 
caution and clinical correlation while establishing the 
diagnosis are suggested.208 
In a biopsy specimen. minimal diagnostic criteria for 
chronic rejection are the presence of foam cell OA or con-
vincing evidence of bile duct loss (>50% of the triads) doc-
umented by the presence of hepatic artery branches with-
out bile ducts or by the absence of both ducts and hepatic 
artery branches. 78 The diagnosis is strengthened if the pa-
tient had documented episodes of acute rejection that had 
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progressed to chronic disease and prolonged liver dys-
function that had not responded to appropriate anti-
rejection therapy.4, 12, 1',78, 167, 187-191, 205 
Duct loss is determined by calculating the ratio of the 
number of hepatic artery branches and the number of bile 
ducts within a portal tract (nonnal value is usually 
>0.7).190• 212 The greater the number of triads counted, the 
more likely the count is to be valid, although Ludwig and 
colleagues suggested that at least 20 portal tracts should be 
included.77• 78, 194 Study of several sequential biopsy speci-
mens, obtained over a period of3 to 6 months, may be re-
Quired to examine a sufficient number oftriads.77, 189, 194 
Recognition of portal triads may be difficult in cases 
in which the hepatic arterioles have also been des-
troyed. I90,206 
The presence of foam cell arteriopathy can rarely be 
confirmed by a core needle biopsy (see Fig 69- 14). Fea-
tures in a peripheral needle biopsy that suggest but do not 
prove the presence offoam cell arteriopathy include loss of 
arterioles and small arteries «20 ,urn) in greater than 20% 
of the portal tracts, centrilobular hepatocellular swelling, 
perivenular sclerosis, and centrilobular hepatocyte 
dropout.4. 12. 15.78.167.187-191. 205 
Portal inflammation can be mild in chronic re-
jection, but, despite a relative paucity of portal inflam-
mation, intraepithelial lymphocytes located adjacent 
to pyknotic or apoptotic biliary epithelial cells are 
seen.4. 12. 15.78. 167, 187-191.205 Characteristic degenerative 
changes of the biliary epithelium include uneven spacing 
of individual epithelial cells, eosinophilic transformation 
of the cytoplasm similar to that observed in primary bili-
ary cirrhosis, and ducts only partially lined by epithelial 
ceils. As the lesion progresses, bile ducts become difficult 
to identify. Special stains (eg, trichrome, PAS-D, and cy-
tokeratin) may be used to enhance their detection by high-
lighting the basement membrane or selectively staining 
the biliary epithelial cells. Eventually, the bile ducts are 
completely destroyed and are replaced by fibrous tissue: 
the smaller the duct, the more susceptible it is to damage 
and loss. 190.205 
Other portal tract alterations in chronic rejection in-
clude "collagenization" of the connective tissue with loss 
of portal capillaries, small arteriole loss or mural thicken-
ing, subintimal foam cells, and fibrosis (see Fig 69 - 14). 
Significant ongoing, piecemeal necrosis or cirrhosis 
caused by chronic rejection is uncommon in our experi-
ence but has been observed by Wight.26 
Lobular changes in chronic rejection include centrilo-
bular hepatocanalicular cholestasis. intrasinusoidal foam 
cell clusters, mild spotty acidophilic necrosis of hepato-
cytes, centrilobular hepatocyte atrophy. and ballooning 
and perivenular sclerosis.4. 12. 15.78. 167. 187-191 .20' The clus-
ters of foamy macrophages, although common, may 
simply represent a nonspecific response to cholestasis: 
therefore. alone, they are not diagnostic of chronic re-
jection. The centrilobular degeneration and perivenular 
sclerosis may be related to either ischemia or damage 
from repeated bouts of "central venulitis" during 
acute rejection . I . 2. 76. 77. 208 
In an explanted failed allograft, the diagnosis of chronic 
rejection is easier to establish. The presence of foam cell 
OA should be seen in at least some of the muscular arteries 
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Figure 69-14 Chronic rejection. A, In a needle biopsy, chronic rejection is characterized by loss of 
bile ducts, as shown here, along with collagenization of the portal tract (PT) connective tissue and, at 
times. loss of the small hepatic arterial branches. Lobular hepatocanalicular cholestasis (arrows) is 
seen in the later stages. B, Obliterative arteriopathy is the defining feature of chronic rejection, but it is 
rarely detectable in a needle biopsy unless a relatively large artery is inadvertently sampled, as shown 
here (arrows). C, Obliterative arteriopathy is more often unequivocally detected only in the failed 
allograft hepatectomy specimen (arrows). D, A higher magnification of the affected arteries shows 
subintimal deposition of foam celis, which consist of lipid-laden macrophages and foamy 
transfonmation of intimal and mural myocy1es. 
in the hilum. I. 2, 4. 12. IS. 78,167. 187-191, 20S Arteries affected 
by OA most commonly show luminal narrowing because 
of subintimal deposition of lipid-laden cells that derive 
from macrophages and intimal and medial myocytes (see 
Fig 69-14). However, Iymphohistiocytic intimal inflam-
mation, smooth muscle cell proliferation, disruption of 
the elastic lamina, and periadventitial and intramedial in-
flammation may also be present.204 Affected vessels may 
also contain immunoglobulin and complement de-
posits.213 Major hilar bile ducts may show sloughing of the 
epithelium, focal necrosis. papillary intraluminal hyper-
plasia. mural fibrosis. and acute and chronic inflamma-
tion.213 Foamy macrophages may also be seen around bile 
ducts and veins in the connective tissue. 
The diagnosis of chronic rejection is difficult and uncer-
tain in the early stages before overt bile duct loss involving 
greater than 50% of the triads is evident. 78 Such cases usu-
ally show only mild portal inflammation. but the biliary 
epitheliiJm shows eosinophilic transformation of the cyto-
plasm. intraepitheliallymphocytes. and uneven spacing of 
the nuclei, with only partial lining of the ductular circum-
ference by epithelium.30· m, 214 Cholestasis may not be 
present at this stage. The diagnosis in the earlier stages is 
strengthened by repeated biopsies and clinical correlation. 
which typically show a patient with documented acute re-
jection that has progressed to chronic injury and pro-
longed liver dysfunction that has not responded to appro-
priate antirejection therapy.78 Such cases would be 
categorized as "rejection, indefinite for dUCI loss" by the 
World Congresses of Gastroenterology consensus panel. 78 
GRADING AND STAGING. A tentative scheme for the 
grading of liver allograft rejection. which is indefinite for 
bile duct loss (discussed later) and chronic rejection (Table 
69-5) has been proposed by the NIDDK liver patholo-
gists l86 but has not yet been tested for reliability or prog-
nostic significance. As in acute rejection. the arteries af-
fected by rejection-related causes are usually not present 
in needle biopsies. Therefore. grading of severity is based 
on "surrogate" markers of OA. 
TABLE 69- 5 . NIDDK definitions of grades for chronic rejection 
and for rejection, Indefinite for chronicity (Indefinite for bile duct 
loss)'" 
Rejection, Indefinite for Chronicity (Indefinite for Bile Duct Loss) 
I. No complicating lobular changes 
2. Lobular changes, including one of the findings: centrilobuJar 
cholestasis, peri venular sclerosis, hepatocellular baUooning or necrosis 
dropout ' 
Chronic (Ductopenic) Rejection" 
I. Bile duct loss without centrilobular cholestasis. perivenular 
sclerosis, or hepatocyte baUooning or necrosis and dropout 
2. Bile duct loss with one of the following four findings: centrilobular 
chotestasis, perivenular sclerosis, hepatocellular baUooning or necrosis, 
dropout 
3. Bile duct loss with at least two of the following four findings: 
centnlobular chotestasis, peri venular sclerosis, hepatocellular 
ballooning or centrilobular necrosis, dropout 
'Bile duct loss in > 50% of triads. 
NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases. 
From Demetris AJ. Bans EC. FerreU L. et aI. Reliability and predictive value of 
the NIDDK liver transplant database nomenclature and grading system for 
cellular rejection of liver aUografts. Hepatology 21 :408-416.1995. 
Differential Diagnosis. The differential diagnosis of 
chronic rejection is limited to a few conditions, but as de-
scribed previously, establishing the diagnosis with cer-
tainty is difficult, particularly in the early stages. More-
over, focal bile duct loss in a single biopsy does not 
necessarily indicate a widespread process. Other condi-
tions associated with bile duct loss and cholestasis in a liver 
allograft include biliary tract obstruction and drug- or 
virus-related bile duct injury and loss.208 
An unequivocal diagnosis of chronic rejection can be 
rendered only if a medium-size artery is sampled that 
shows foam cell OA.186 Unfortunately, this is an extremely 
rare occurrence. Therefore. one is forced to rely on bile 
duct loss associated with the cholestasis and other lobular 
changes described previously. The safest approach is to re-
view prior biopsies and closely correlate the histopatholo-
gical findings with the clinical course. Bile duct loss in a 
patient who has experienced multiple or refractory epi-
sodes of acute rejection, who experienced a previous failed 
graft from chronic rejection. or who harbored preformed 
Iymphocytotoxic antibodies and showed a progressive de-
cline in ducts and liver function is more likely to be due to 
chronic rejection.78 In addition to the biopsy findings, the 
decision to proceed with retransplantation should be 
based on clinical parameters such as a progressive decline 
in synthetic function. superimposed hepatic artery throm-
bosis. and bile duct necrosis or biliary sludging. Primary 
reliance on decline ofliver function and clinical morbidity 
is urged because bile duct loss and jaundice have sponta-
neously resolved without clinical intervention in some pa-
tients. 189. 209. m In our FK506 rescue protocol,2t6. 217 we 
found that patients whose bile duct loss exceeded 50% of 
the triads and whose bilirubin level was higher than 10 
mg/dl responded to therapy for chronic rejection much 
less frequently than those with less severe damage.108 
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Graft-Versus-Host Disease 
Acute GVHD is most commonly seen after allogeneic 
bone marrow transplantation, although reports in recipi-
ents of un irradiated blood products that contain allogen-
eic leukocytes are not uncommon. Prerequisites of this re-
action include immunocompetent mature donor T cells 
and a defenseless, or at least weakened, recipient immune 
system.218 The donor T cells, carried with the allograft in 
the interstitium and hilar lymph nodes,219 respond to re-
cipient MHC-bearing cells that include relatively imma-
ture epithelial cell populations in the basal layers of the 
skin, gastrointestinal tract, liver, and lung. A more in-
depth discussion of GVHD is beyond the intended scope 
of this text.218 Nevertheless, GVHD further suppresses re-
cipient immunity and predisposes to both bacterial and 
viral infection. Moreover, donor B cells can produce an-
tirecipient antibodies that cause lysis of recipient red 
blood cells and hematolymphoid cells" l , 220 
Clinical Presentation. Patients usually present during 
the first 6 months after transplantation with a fever, rash, 
and, at times, diarrhea.84. 100-102 In ABO-compatible but 
mismatched cases, GVHD disease can take the form of red 
cell hemolysis and pancytopenia.2lO The diagnosis of the 
more conventional type of GVHD is confirmed by de-
tailed analysis of a tissue biopsy specimen usually taken 
from the skin or gastrointestinal tract. 221.222 "Humoral" 
GVHD can be diagnosed by determining the nature of the 
red cell antibody responsible for hemolysis. 
Histopathological Findings. Of course, the liver allo-
graft is not susceptible to GVHD in a liver allograft recipi-
ent. Histopathological findings of GVHD in non hepatic 
tissues are identical to those described for GVHD after 
bone marrow transplantation. In the skin, a mild, mixed, 
lymphocytic, and eosinophilic infiltrate in the upper retic-
ular and papillary dermis is typically associated with lym-
phocytic exocytosis, spongiosis. acidophilic necrosis of in-
dividual keratinocytes and epithelial cells surrounded by 
lymphocytes ("satellitosis") (Fig 69 - 15). Unfortunately, 
indistinguishable histopathological findings may also be 
present because ofa viral exanthem or an adverse drug re-
action.221 In the intestines. there is usually no increase in 
the number of inflammatory cells above those already 
present. Instead, one usually finds apoptosis in crypt epi-
thelial cells without viral inclusions.222 Disease severity 
progresses in a fashion similar to that described for bone 
marrow allograft recipients. More severe GVHD in the in-
testine manifests as crypt abscesses with focal areas of 
crypt destruction and ultimately areas of mucosal necrosis 
and sloughing; it manifests in the skin by formation of 
bullae and epidermal sloughing. 
Differential Diagnosis. In the skin. the two most com-
mon syndromes mimicking acute GVHD are adverse 
drug reaction and a viral exanthem. In the gastrointestinal 
tract, GVHD is most similar to CMV enteritis without ob-
vious inclusion bodies. Distinguishing G VHD from these 
entities using routine histopathological findings alone is 
extremely difficult if not impossible. In addition to a de-
tailed clinical history (including a list of medications. pos-
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Figure 69-15 A. Graft-versus-host disease of the skin in a liver allograft recipient is identical to that 
described for patients after bone marrow transplantation. with a mild mixed infiltrate in the papillary 
dermis and lymphocytic exocytosis (arrow) . B. Higher magnification showing lymphocytic infiltration of 
the epidermis and spongiosis. 
sible allergies, and other infections), stains for CMV anti-
gens and the use ofanti-MHC monoclonal antibodies or 
in situ hybridization for the Y chromosome to identify 
donor cells are extremely useful.84 The presence of an oc-
casional donor cell in the skin or gastrointestinal tract is 
usual because of the hematolymphoid trafficking and is 
not diagnostic ofGVHD. However, the presence of many 
donor celis, preferentially distributed to the areas of tissue 
damage, confirms a diagnosis of GVHD (Fig 69 - 16). 
Figure 69-18 Immunoperoxidase staining for mismatched major 
histocompatibility complex antigens as shown here. or the Y 
chromosome in male-to-femaJe transplants. confirms the presence of 
donor cells and graft-versus-host disease when tissue damage is 
present. 
BACTERIAL AND FUNGAL INFECTIONS 
The first 2 months is the critical time for the most serious 
opportunistic fungal and viral infections. 223 Thereafter, 
most infections are due to bacterial pathogens. Clinical 
histories that should also arouse the suspicion of an infec-
tion include anastomotic or wound dehiscence, retrans-
plantation, fever, persistent abdominal pain, and vascular 
thrombosis. However, a high index of suspicion should 
always be maintained. 
Any nonviable hilar tissue removed from the allograft 
or from the immediate vicinity is routinely subjected to 
special stains (Gram's and Grocott's) for the detection of 
micro-organisms. A caveat for the pathologist to re-
member is that inflammation may be mild or absent be-
cause of immunosuppression. and organisms are easily 
overlooked on H&E stains alone (see Fig 69- 7). 
The histopathological changes associated with bacterial 
or fungal infections of tissues are well known to most sur-
gical pathologists and are not discussed. However, histo-
pathologists involved with the care of transplant patients 
are encouraged to have a good working knowledge of the 
histopathological characteristics of superficial and deep 
fungal, bacterial. and viral infections, as referred to early 
in this chapter. The manifestations of these infections are 
not entirely different from those seen in the general popu-
lation, with several exceptions alluded to in each of the 
sections on viral infections. In addition, common derma-
tophytes can cause deep infections of the skin or visceral 
organs (unpublished observation). In such cases, the final 
diagnosis was arrived at by being unable to classify the 
fungal pathogens on morphological criteria alone and on 
the basis of the growth of dermatophytes in cultures of the 
tissue specimens. 
VIRAL INFECTIONS 
Liver allograft recipients are highly susceptible to and fre-
quently acquire viral hepatitis. Many have been chroni-
cally infected with the hepatitic viruses, such as hepatitis 
B, C, and D viruses (HBV, HCV, HDV, respectively) be-
fore transplantation. After transplantation, they receive 
multiple blood products and require potent immunosup-
pression, which makes them susceptible to opportunistic 
hepatitis viruses, such as CMV, Epstein-Barr virus (EBV), 
herpes simplex virus (HSV), and varicella-zoster (VZ), 
that do not usually cause hepatitis in the general pop-
ulation. 
In general. the histological appearance of viral hepatitis 
in the liver allograft is similar to that observed in non-
grafted livers from immunosuppressed patients and to 
viral hepatitis in the general population. In addition, be-
cause of the potent immunosuppression and allogeneic 
liver, there are pathophysiological presentations of viral 
hepatitis that are unique to the liver allograft recipient. 
Clinical Presentation. It is helpful to anticipate the time 
of.onset of the different viral syndromes (see Table 69 - I). 
It IS also helpful to know that recipients who are seronega-
tive for opportunistic viral pathogens like CMV. EBV, 
HSV -VZ. and adenovirus and receive seropositive organs 
show an increased incidence and severity of disease after 
transplantation. Furthermore, although blood product 
screening for HBV and HeV is routine. de novo infection 
with these pathogens in a liver allograft recipient is not 
rare.Treatment of opportunistic pathogens usually in-
volves lowering of immunosuppression and addition of an 
effective antiviral drug, such as acyclovir. The "hepatitic" 
viruses are a particular problem. because the current drug 
arsenal used to treat them is not very effective. and may 
precipitate rejection. Furthermore, lowering immunosup-
pression can. in some cases. exacerbate the disease. 
HEPATITIC VIRUSES 
Hepatitis B and Delta Co infection 
HBV infection with or without delta coinfection is largely 
restricted to patients whose original liver disease was 
caused by this virus. 13. 224-234 Virtually all patients who 
show evidence of viral replication before transplantation 
(ie. hepatitis Be antigen [HBeAg] seropositive or HBV 
DNA - positive) will experience reinfection of their allo-
graft and hepatitis after transplantation. Allograft reinfec-
tion and disease are less predictable in patients who had 
HBV-induced fulminant liver failure or in those with 
chronic liver disease who had become anti-HBe positive 
and serum HBV DNA and HBeAg negative before 
transplantation. 13. 224-234 Approximately 10 to 25% of the 
latter patients will not experience reinfection of the allo-
graft. nor will they experience HBV disease. Despite donor 
and blood product screening. a small number of patients 
without previous HBV disease will acquire HBV infection 
during or after transplantation. 
Because of the high incidence of recurrence. various 
treatment modalities have been used in an attempt to 
break the cycle of reinfection. These include hepatitis B 
immune globulin. active vaccination with hepatitis B sur-
face antigen (HB.Ag). INF-a. and human monoclonal 
anti-HB,. Although none of these therapies appears 
to be entirely effective in preventing reinfection. a later 
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onset of disease recurrence and amelioration of liver in-
jury have been reported with continuous high-dose anti-
HB.Ag therapy. 13. 224-234 The high infectivity ofHBV and 
the documentation of extrahepatic reservoirs of HBV 
probably account for the difficulties encountered in eradi-
cating the virus. 
Pathophysiology. It is beyond the scope ofthis chapter to 
delve into a detailed discussion of the pathophysiology of 
HBV-induced liver disease; however, some pathophysio-
logical presentations and observations unique to the allo-
graft recipient could provide useful insights into the over-
all disease pathogenesis. Under normal circumstances, 
HBV is not thought to be cytopathic. Liver damage is 
thought to be at least partially attributable to the expres-
sion of hepatitis B core antigen (HB.,Ag) on the surface of 
hepatocytes, which then become targeted for destruction 
by MHC-restricted CTLs.m. 236 Alternatively, in the allo-
graft. the processing of viral antigens by periportal recipi-
ent accessory cells and their MHC class II - restricted pre-
sentation to T lymphocytes in a fashion resembling a 
delayed-type hypersensitivity response may be in-
volvedKOO~K 237 
It should be remembered that CTL lysis of virally in-
fected parenchymal cells is MHC restricted. and identity 
between the donor and recipient is a matter of chance. 
There is no attempt at prospective MHC matching in clin-
icalliver transplantation.m . 237 There are too few cases at 
this time to draw any definite conclusions about the rela-
tionship of MHC matching or mismatching and HBV dis-
ease pathogenesis. Massive viral replication in class II 
MHC-mismatched deteriorating liver allografts with lit-
tle or no hepatic inflammation prompted several groups to 
suggest that. under special circumstances. the virus may be 
directly cytopathicKOO~ K 227-229. 238. 239 
Clinical Presentation. HBV hepatitis usually occurs 6 to 
8 weeks after transplantation . The presentation varies 
from mild elevations of liver injury tests to nausea. vomit-
ing. jaundice. and hepatic failure . The clinical syndrome, 
therefore, is not significantly different from viral hepatitis 
seen in other immunosuppressed or even nonimmuno-
suppressed patients in the general population.13. 224-234 
Needle biopsy evaluation confirms the diagnosis. 
Histopathological Findings. The histopathological pre-
sentation of hepatitis B infection in the hepatic allograft 
is similar to that seen in nonallograft livers. although 
local treatment policies can apparently influence the 
onset and severity of the histopathological find-
ings. 13. 224-232. 234. 238. 239 In the majority of patients who 
eventually experience chronic disease. there is a typical 
progression from an acute to a chronic hepatitis. and cir-
rhosis can develop with striking rapidity. 13. 224 -
231. 234.238.239 However. occasional patients will show his-
topathological resolution of disease activity after a bout of 
acute hepatitis, and rare patients will actually " clear" the 
virus after transplantation. There also are several patho-
physiological presentations of HBV unique to the liver 
allograft that are likely related to the potent immunosup-
pression and MHC nonidentity between the liver and 
recipient. 
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In the majority of patients, acute viral hepatitis type B 
presents in a predictable fashion, first manifest within sev-
eral weeks after transplantation by the appearance of cyto-
plasmic hepatitis core antigen in an occasional hepato-
cyte. Characteristically, the infection, and thus core and 
surface antigens, spread throughout the liver to involve a 
large number of cells, 13,224-232,234,238,239 and then lobular 
necroinflammatory activity, Kupffer cell hypertrophy, lo-
bular disarray, and varying amounts of portal inflamma-
tion mark the onset of acute disease (Fig 69 - 17). Even 
though patients are immunosuppressed, a small number 
can experience bridging or even submassive necrosis at 
this stage, particularly if immunosuppression is with-
drawn.224 A few other patients show resolution of the acute 
necroinflammatory activity but persistence of infection. 
A more common scenario is evolution into chronic dis-
ease. This is characterized by lymphoplasmacytic portal 
inflammation with relative sparing of the bile ducts and 
portal veins and varying degrees of piecemeal necrosis 
characterized by extension of lymphocytes and macro-
phages into the edge of the lobule combined with cholan-
giolar proliferation (Fig 69 - 18). Lobular findings typical 
of the chronic phase of infection include a large number of 
cells with a ground glass cytoplasm containing HB,Ag and, 
on occasion, numerous hepatocytes with sanded nuclei 
filled with HB.,Ag. This is accompanied by varying degrees 
of lobular disarray, regeneration, Kupffer cell hyper-
trophy, and lobular necroinflammatory activity. 
c 
Several patterns ofliver injury associated with HBV are 
not commonly encountered in the general population, 
and are probably (but not definitely) related to effects of 
immunosuppression and MHC non identity between the 
liver and recipient.22s, 227-229, 238-240 The first is character-
ized by marked hepatocyte swelling, lobular disarray, and 
cholestasis, with only mild or no portal or lobular inflam-
mation and varying degrees of cholangiolar proliferation. 
Such cases are usually marked by massive hepatocellular 
production of core and surface antigen, in association with 
the hepatocyte degenerative changes including cell swell-
ing, steatosis, and necrosis (Fig 69 - 19). Follow-up biop-
sies may reveal progressive portal and periportal sinusoi-
dal fibrosis and lobular collapse often without a significant 
inflammatory component.22S, 227-229, 238-240 High levels of 
viral replication and antigen expression in these cases have 
led several groups to suggest that HBV may be directly cy-
topathic under the special circumstance of an allograft 
liver in an immunosuppressed patient.m , 227-229, 238-240 
The Cambridge group suggested the termfibrosing choles-
lalic hepalilis228 to describe this lesion, whereas Benner et 
aJ239 preferred fibrosing cytolytic hepatilis to describe a 
similar, ifnot the same set of. findings. Phillips et al238 also 
emphasized the heavy viral burden in liver allograft recipi-
ents, which caused swelling of the endoplasmic reticulum 
and hepatocellular degenerative changes. They drew par-
ticular attention to the presence of hepatocellular steatosis 
and also coined the terms steatoviral and fibroviral hepati-
Figure 69-17 A. Acute hepatitis type B is most often similar to the 
acute hepatitis seen in the general population. It is characterized by 
portal inflammation of varying severity. accompanied by lobular 
disarray. Kuptfer cell hypertrophy. and spotty acidophilic necrosis of 
hepatocytes (arrows). B. A higher magnification shows the typical 
lobular findings associated with acute viral hepatitis. C. Occasionally. 
severe acute disease can result in bridging necrosis. as shown here. 
particularly if immunosuppression is withdrawn. 
Figure 69-18 A. Chronic hepatitis type B often appears histopathologically similar to chronic 
hepatitis B in the general population. characterized by mononuclear portal Inflammation with spillover 
of the infiltrate into the edge of the lobules and associated with periportal hepatocyte necrosis and 
relative sparing of the bile ducts (arrows) (pt = portal tracts). B. A higher magnification illustrates the 
periportal activity. intact bile duct (arrow). and expression of hepatitis B core antigen in the nuclei of 
hepatocytes (arrowhead). (A and B from Demetris AJ. Todo S. Van Thiel DH. et al. Evolution of 
hepatitis B virus liver disease after hepatic replacement: Practical and theoretical considerations. Am J 
PathoI137:667-676. 1990.) 
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tis B, accentuating the features of fat and fibrosis.238 The 
exact relationship between the new terms proposed by 
Phillip et aJ238 and those proposed by Benner239 and 
Davies228 and their colleagues is uncertain, but in general 
they appear to describe a similar set of findings. More im-
portant, this relatively unique presentation in the allograft 
could provide useful insights into disease pathogenesis. 
marked cytological distortion of the hepatocytes, lobular 
disarray, and mild necroinflammatory lobular activity. 
Finally, a massive overproduction of the surface antigen 
can be seen in the allograft liver, with the vast majority of 
hepatc . v1es containing a ground glass cytoplasm, similar 
to that in HB.Ag transgenic mice.241 This results in 
In patients with histopathological features compatible 
with one of these presentations, immunohistochemical 
staining for HB.Ag and HBcAg using polyclonal reagents 
are utilized to detect viral antigens. Our experience with 
monoclonal anti-HBV reagents has yielded results of 
higher specificity but lower sensitivity. Patients with cyto-
plasmic HBcAg expression have experienced a more ag-
gressive course in our experience (unpublished obser-
vation). 
Figure 69-19 " Fibrosing dlolestatic" hepatitis. viral type B. A. Note the prominent central-centraJ 
and portal-central distribution of swollen and degenerating hepatocytes and paucity of inflammation 
(p = portal; c = central) . B. The massive viral replication in the degenerating hepatocytes 
(immunoperoxidase stain for hepatitis B core antigen) in such cases suggests that the virus may be 
directly cytopathic in some circumstances. (From Demetris AJ. Todo S. Van Thiel DH. et al. Evolution 
of hepatitis 8 virus liver disease after hepatic replacement: Practical and theoretical considerations. 
Am J Pathol137:667 -676. 1990.) 
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As in the general population, delta agent coinfection 
may complicate reinfection of the allograft by HBV. Fol-
low-up of such patients has yielded somewhat conflicting 
results, with reports of both more and less severe disease 
after transplantation.232, 214, 242-W In addition, there are 
conflicting reports about the cytopathic effect of HDV 
after transplantation and its relationship to HBV replica-
tion. David et al246 noted that HDV associated with 
nonreplicative HBV infection resulted in hepatitic lesions 
similar to those described as "fibrosing cholestatic," "fi-
brosing cytolytic," or "steatoviral" hepatitis but without 
HB.,Ag expression in the liver. In contrast, when active 
HBV replication was present, the HBV plus HDV hepati-
tis in the allograft produced necroinflammatory activity 
similar to that seen in viral hepatitis types Band D in pa-
tients from the general population.246 
Differential Diagnosis. Acute hepatitis B is most often 
confused with acute hepatitis caused by other viruses. Dis-
tinction is usually achieved with the aid of special studies 
to detect viral antigens or nucleic acids in the blood or tis-
sues or antibody reactions to the virus. Acute rejection and 
acute hepatitis can also be confused with each other at 
times.224. m Histopathologically, the lobule is the focus of 
injury in acute hepatitis. Spotty hepatocyte necrosis, dis-
array, and lobular necroinflammatory activity with vary-
ing degrees of portal inflammation are the usual findings. 
In contrast, immune damage in acute rejection is primar-
ily directed at the portal structures, including the portal 
vein and bile ducts and portal inflammation is invariably 
present. 224. 225 
Difficulties can be encountered when trying to separate 
late-onset acute and chronic rejection from chronic "per-
sistent" or chronic hepatitis with low-grade activity in 
cases in which no ground glass hepatocytes or sanded nu-
clei are seen . Prominent piecemeal necrosis, damage of 
only an occasional bile duct, periportal bridging necrosis 
and lobular disarray, and necroinflammatory activity usu-
ally are not features of acute rejection and thus point 
toward hepatitis as the cause of malfunction. In contrast, 
damage of more than an occasional bile duct and bile duct 
loss are not generally seen in hepatitis and point toward 
rejection. There also are occasional cases in which the sep-
aration of acute rejection and chronic hepatitis will not be 
possible. 7I · 208. m In such cases, our policy is to err toward 
overtreating viral hepatitis as rejection . 
Finally, infection of the allograft by HBV does not 
equate with HBV disease or, for that matter, exclude re-
jection.m Detection of either the core or surface antigen 
by immunohistochemistry may be seen in an allograft that 
otherwise has all the features of acute or chronic rejection. 
Several patients have persistently harbored HBV in the al-
lograft but have experienced graft failure because of bile 
duct loss and OA.m 
Hepatitis C Virus 
Recurrent and de novo HCV infection is becoming recog-
nized as a more serious problem in liver transplantation 
than originally thought. Earlier studies evaluating rates of 
recurrent infection and disease severity were based on ser-
ological evidence of infection, which clearly underesti-
mated the extent of the problem because of a poor immu-
nological response to the virus after transplantation.247-251 
The rate of recurrent infection, on the basis of reverse tran-
scriptase polymerase chain reaction (RT-PCR) testing of 
serum and tissues, is extremely high, being 90% or more in 
some centers.2S2-2S7 Data on the incidence and severity of 
HCV-related disease in the posttransplant population are 
just beginning to accumulate.2s2-2n Currently, it is esti-
mated that a majority of those reinfected experience acute 
hepatitis, whereas 2 to 60% go on to have chronic HCV-
related disease activity.252-2s7 The difference in chronic 
disease severity at various centers is likely related to sev-
eral factors, including immunosuppression policies, 
lengths of follow-up, methods of viral detection, use of an-
tiviral therapy, and frequency of needle biopsy evaluation. 
Clinical Presentation. The clinical presentation ofHCV 
hepatitis is virtually identical to that seen in the general 
population. Many times, the early phases of the disease 
may be asymptomatic, detectable only by an elevation of 
liver injury test findings, which are frequently monitored 
in this patient population. Fatigue, nausea, jaundice, and 
other typical signs of acute hepatitis are less frequent, and 
fulminant liver failure is rare.2H- m Needle biopsy evalua-
tion is used to confirm the diagnosis. 254. m 
Histopathological Findings. The histopathology of viral 
hepatitis type C in the liver allograft recipient is not sub-
stantially different from that seen in the general popula-
tion, although, as is the case for hepatitis B, there are path-
ophysiological presentations unique to the allograft 
recipient. I I, 28, 31, 254, 158 Similar to HBV, the acute stage is 
characterized by findings typical of acute viral hepatitis 
such as lobular disarray, Kupffer cell hypertrophy, spotty 
acidophilic necrosis of hepatocytes, and variable portal 
and lobular inflammation.28. 30, 31.254.258 Findings of more 
severe acute disease include bridging and confluent ne-
crosis, although submassive necrosis caused by HCV in 
liver allograft recipients is rare. 
Unresolved cases of HCV can then evolve into the 
chronic phase characterized by nodular portal lymphoid 
aggregates (Fig 69-20), piecemeal necrosis, mild mid-
zonal or periportal macrovesicular steatosis, sinusoidal 
lymphocytosis (beading), and damage to an occasional 
bile duct, similar to that described in the general 
population.254, m-26O Atypical histopathological features 
of HCV described in liver allograft recipients include 
centrilobular hepatocellular swelling, ductular prolifera-
tion, and acute cholangiolitis with portal fibrosis (see Fig 
69 - 20), similar to "fibrosing cholestatic hepatitis" de-
scribed earlier. including the paucity of portal tract 
inflammation.254.258 
The diagnosis of type C viral hepatitis is suspected on 
the basis of histopathological findings and is confirmed by 
showing viral RNA in the liver tissue or serum by RT-
PCR. At present, we have not had much success with im-
munohistochemical staining for viral antigens in routinely 
processed liver biopsies. 
Differential Diagnosis. Acute HCV hepatitis must be 
separated from acute hepatitis caused by other viruses 
such as HBV. CMV, and EBV. CMV hepatitis usually 
--. 
A 
c 
shows less lobular disarray, and instead of diffuse lobular 
inflammation or sinusoidal lymphocytosis, CMY hepati-
tis typically shows distinct clustering of the lobular infil-
trate into microabscesses or microgranulomas. Nuclear 
and cytoplasmic inclusions are seen in CMY and not in 
HCY. EBY hepatitis in an allograft recipient261-268 is more 
difficult to separate from hepatitis C on the basis of histo-
pathological findings alone. Both show sinusoidal lym-
phocytosis, although atypical lymphocytes are present in 
EBY and not in eCyKO~4K m EBY hepatitis may also con-
tain microgranulomas.261-266 Moreover, the clinical pro-
file of patients with EBY hepatitis is different from that of 
HCY patients, I and, fortunately , use ofRT-PCR for HCY 
and in situ hybridization for EBY are useful for distin-
guishing between them in tissue sections. 
The differential diagnosis for chronic HCY hepatitis in-
cludes acute and chronic rejection, recurrent non-HCY 
viral hepatitis, recurrent autoimmune chronic hepatitis, 
recurrent primary biliary cirrhosis, and recurrent primary 
sclerosing cholangitis as well as bile duct obstruc-
tion. 7I · O~4K O~U Exclusion of chronic HCY liver disease is 
based on the absence ofHCY by tissue RT-PCR. HBY is 
identified on the basis or viral antigens, which are invari-
ably present and detected in the serum or with immuno-
peroxidase staining of tissue specimens. Recurrent pri-
mary biliary cirrhosis is recognized on the basis of 
portal-based granulomas, minimal lobular activity , and 
the evolution of a "biliary" fibrosis, which is not seen with 
chronic HCy.7I· 123.269-272 
Cholestatic hepatitis is difficult to differentiate from bile 
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Figure 69 - 20 Chronic hepatitis type C. A. In the chronic stages. 
portal inflammation of varying severity. often arranged into nodular 
aggregates. as shown here. piecemeal necrosis. and necrogenic and 
regenerative activity in the lobule are common. B, Higher 
magnification shows the mononuclear portal infiltrate un associated 
with significant bile duct injury or loss (arrow) and focal spillover into 
the edge of the lobule (arrowhead). C, Not infrequently, hepatitis C 
virus will present as a "cholestatic hepatitis" with marked cholangiolar 
proliferation, minimal portal inflammation, portal fibrosis, and lobular 
hepatocanalicular cholestasis. 
duct obstruction and hepatic artery thrombosis. Portal 
edema and portal, rather than periportal, neutrophilia are 
common in duct obstruction and acute cholangitis. 
whereas cholangiolar proliferation and acute cholangio-
litis without portal edema are more characteristic of cho-
lestatic hepatitis. In addition. lobular disarray and marked 
hepatocellular swelling are more usual for viral hepatitis in 
contrast to duct obstruction. 
Acute and chronic rejection may be difficult to separate 
from chronic viral hepatitis C. mostly because both are 
characterized by portal inflammation and bile duct dam-
age. However, in acute or chronic rejection , bile duct dam-
age and loss involve more than an occasional duct, 
whereas in HCY only an occasional bile duct is dam-
aged. 71 In addition, lobular disarray is unusual for rejec-
tion but is common in hepatitis. Furthermore, centrilobu-
lar inflammation, fibrosis, and hepatocellular dropout 
present in more than an occasional central vein, are more 
often seen in rejection than in viral hepatitis. Unfortu-
nately, it is not always possible to separate rejection from 
hepatitis on the basis of the histopathological findings 
alone. 71 , 208 In our experience. we prefer to err on the side 
of overdiagnosis of rejection. 
Hepatitis Types A and E 
We have not as yet identified hepatitis types A and E as 
causes of allograft dysfunction. However, Fagan et aim 
showed hepatic persistence or reinfection of a liver allo-
graft of a recipient who required transplantation for ful-
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minant hepatic failure because of the hepatitis A virus. Ex-
trahepatic reservoirs of the virus were thought to account 
for reinfection and hepatitis of the allografted liver. On the 
basis of these and the prior observations for hepatitis types 
B, C, and 0, it might be expected that hepatitis in a liver 
allograft caused by these viruses would appear similar to 
that seen in nonallografted livers. 
Hepatitis Type F 
Several patients identified at the University of Pittsburgh 
have experienced a classic chronic hepatitic histopatholo-
gical profile but without evidence of hepatitis B, C, or 0 
infection, and other causes of allograft dysfunction were 
reasonably excluded. Therefore, it appears that there may 
be yet another hepatitic virus capable ofreinfecting a liver 
allograft. At least one of these patients experienced liver 
failure in two successive allografts but was repeatedly RT-
PCR negative for hepatitis C virus in liver tissue. 
OPPORTUNISTIC VIRUSES 
Cytomegalovirus Hepatitis 
CMV is the most commonly encountered opportunistic 
viral infection of the liver allograft recipient. Symptomatic 
disease is usually encountered during or after bolstered 
immunosuppressive therapy (eg, treatment of rejection) 
between 3 and 8 weeks post transplant. The infection may 
be the result of recrudescence in a carrier, transmission 
through blood products or the donor organ, or acquisition 
from other sources in the environment. Seronegative re-
cipients who receive seropositive donor organs are at the 
greatest risk for symptomatic disease.274 - 284 Viral infec-
tion and latency in granulocytes or endothelial cells (D. 
Sedmak, personal communication. November 30, 1994) 
and monocytes may explain the early appearance of viral 
antigens in the sinusoidal cells. Z74 
Clinical Presentation. Signs and symptoms of active 
CMV infection include fever, leukopenia and modestly 
elevated liver injury test results. although any organ sys-
tem can be involved depending on the extent of viral dis-
semination. More frequent complications include 
diarrhea. gastrointestinal ulcers, and hepatitis. 274 - 284 Res-
piratory insufficiency and retinitis occur when the disease 
is severe. The morbidity and mortality ofCMV infection 
are also associated with viral dissemination. Occasionally, 
the disease can mimic the posttransplant syndrome as-
sociated with the EBV infection, which includes mild 
liver function abnormalities, lymphadenopathy, fever. 
and atypical lymphocytosis on the peripheral blood 
smear. 274- 284 
Histopathological Findings. The histopathological 
manifestations of active CMV infection depend. in part. 
on the immune status of the host. In excessively immuno-
suppressed patients who have no prior serological evi-
dence ofCMV infection. any cell type of the liver may be 
infected. and viral inclusions are numerous. The cytome-
galic cells contrun a large eosinophilic intranuclear inclu-
sion surrounded by a clear halo. and occasionally small 
basophilic or amphophilic cytoplasmic inclusions are also 
seen. Despite widespread CMV infestation of the liver 
allograft, fulminant liver failure from submassive or 
massive necrosis from CMV alone has never been 
seen.3O· 274-284 
With improved immunological monitoring, effective 
pharmacological therapy, and immunoprophylaxis, over-
whelming CMV infections, like those described pre-
viously, are now uncommon. With the current pharmaco-
logical arsenal, CMV hepatitis is usually characterized by 
spotty lobular necrosis, Kupffer cell hypertrophy, mild lo-
bular disarray, and microabscesses or microgranulomas 
scattered throughout the lobules (Fig 69 - 21). The ne-
crotic hepatocytes or nearby cells may contain nuclear and 
cytoplasmic inclusions and are surrounded by neutrophils 
(microabscess) or cluster macrophages and lymphocytes 
(microgranulomas). Mild plasmacytic and lympho-
cytic portal inflammation, associated with bile duct 
cell infiltration and damage, may also be seen, mimick-
ing, or actually associated with, acute or chronic 
rejection (see Fig 69 - 21). Duct loss has been as-
sociated with persistent infection of the allograft by 
CMV.19', 196, 198, 199,28'-287 On occasion, the characteristic 
parenchymal alterations described previously may be seen 
but without clear evidence of cytomegaly or a nuclear or 
cytoplasmic CMV inclusion. In such cases, immunoper-
oxidase staining for early viral antigen can be used to de-
tect the infected cells. 
In cases resembling EBV hepatitis, needle biopsy of the 
liver allograft will reveal a mild Iymphoplasmacytic portal 
and lobular infiltrate, with blastic and atypical lympho-
cytes present. Microgranulomas are usually seen in the 
lobules, although characteristic CMV inclusions are ab-
sent. Deeper cuts into the block, immunoperoxidase 
stains for EBV and CMV viral antigens, and in situ hybri-
dization for EBV nucleic acids are usually required to dis-
tinguish between CMV and EBV in such cases. 
"Activated" or rapidly dividing tissues such as young 
granulation tissue, proliferating cholangioles seen in is-
chemically damaged livers. edges of infarcts. abscesses, or 
other intraparenchymal defects are fertile soil for CMV 
growth.3O When such tissue is encountered, a more careful 
search for CMV is warranted. 
Differential Diagnosis. Multinucleated cells may be 
seen in CMV hepatitis. simulating an HSV infection. 
However, CMV -infected cells may also conwin small ba-
sophilic or amphophilic cytoplasmic inclusions, which are 
not seen in HSV. Also, the circumscribed zones of coagu-
lative necrosis characteristic of HSV generally are not en-
countered with CMV. 
CMV hepatitis is, for the most part. separable from 
acute hepatitis caused by hepatotrophic hepatitis BorCvi-
ruses. However. individual cases can pose considerable 
difficulties. especially when no CMV inclusions are de-
tected. Moreover. the distinction is important because 
medical therapy for hepatotrophic versus opportunistic 
viral hepatitis is dramatically different; for CMV, ganci-
c10vir is routinely used, whereas for the hepatotropic vi-
ruses. the usual treatment is INF-a. In general, CMV 
causes much less lobular disarray and hepatocyte swelling, 
and the lobular inflammation seen with hepatotrophic vi-
---
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Figure 69-21 Cytomegalovirus (CMV) hepatitis. A, The most common histopathologic findings in 
CMV hepatitis are microabscesses or microgranulomas, randomly scattered throughout the lobules 
(arrows). They consist of small collections of neutrophils (inset) near cells showing cytomegalic change 
and intranuclear and intracytoplasmic inclusions. B, Portal inflammation can also be seen in some 
cases, as shown here, along with cytomegalic change and inclusions (arrow) in the bile duct epithelial 
cells (inset), in which persistent infection of these cells has been associated with bile duct loss. 
ruses is more diffuse, not being clustered in microab-
scesses or m icrogranu lomas. In the end, reliance is placed 
on adjuvant techniques including viral cultures forCMV, 
RT-PCR assays for HCV, immunoperoxidase staining for 
viral antigens (CMV, HBV) or in situ hybridization for 
viral nucleic acids (EBV), all of which are quite helpful in 
identifying the cause of hepatitis. 
A difficult challenge is determining whether the liver in-
jury is due to residual CMV hepatitis or to the onset of 
acute or chronic rejection, because CMV hepatitis most 
commonly occurs in patients who are under treatment or 
have recently completed an augmented immunosuppres-
sive regimen for rejection. Experience with renal trans-
plantation has shown that CMV (and other infections) can 
precipitate an episode of rejection in the allograft. Further 
complicating the issue is the report by O'Grady et a119~ and 
others showing an association between CMV infection 
of liver allograft and chronic rejection. 196. 198. 199. OU~-OUT 
Others have not seen this association.288 Difficulties arise 
in the pathological interpretation of biopsies in which ob-
vious CMV inclusions are not detected, but staining for 
viral antigens is positive and other histopathological find-
ings typically seen with acute rejection or loss of bile ducts 
are also seen. In our experience. the presence ofCMV in-
clusions or antigens in the biopsy specimen is generally 
given priority, and the immunosuppressive therapy is 
lightened and ganciclovir is given. Follow-up biopsy after 
I to 2 weeks. ifliver function abnormalities persist. is used 
to follow therapy. Unfortunately, bile duct loss may de-
velop and persist in such patients. 
Herpes Simplex and Varicella-Zoster Viral Hepatitis 
Both subtypes of HSV (types I and 2) and VZ have been 
identified as causes of liver allograft hepatitis. 28. 30. 31, 289 
They have been seen as early as 3 days after transplanta-
tion but may occur anytime thereafter. The clinical pre-
sentation has included fever. vesicular rashes. fatigue. and 
body pain combined with serological evidence of hepatic 
injury. IfHSV hepatitis goes unrecognized, it may rapidly 
lead to submassive or massive hepatic necrosis, hypoten-
sion, disseminated intravascular coagulation, and meta-
bolic acidosis.289 Fulminant cases usually occur in patients 
without evidence of prior humoral immunity. Early recog-
nition using needle biopsy sampling is particularly crucial 
because effective medical therapy is available. 
Histopathological Findings. Two histopathological pat-
terns of HSV hepatitis have been identified:289 localized 
and diffuse. However, distinction between the two may be 
more related to swiftness in establishing the diagnosis. 
level of immune competence, and evidence of prior im-
munity than to differences in the viral biology. The pat-
tern of injury important to recognize is that of circum-
scribed areas of coagulative-type necrosis, showing no 
respect forthe lobular architecture28, 30, 31, 289 (Fig 69 - 22). 
Ghosts of hepatocytes, intermixed with neutrophils and 
nuclear debris. are seen in the center of the lesions. More 
viable hepatocytes at the periphery may be slightly en-
larged and contain "smudgy" or ground glass nuclei or 
characteristic Cowdry type A eosinophilic inclusions (see 
Fig 69 - 22). We have not been able to distinguish reliably 
between HSV and VZ on the H&E slides alone. Multinu-
cleate cells are occasionally present. but. not infrequently, 
no changes diagnostic of HSV or VZ will be detected on 
the H&E side. In such cases. immunoperoxidase stains for 
HSV antigens can be confirmatory. Some antibody prepa-
rations used to detect HSV SUbtypes show considerable 
cross-reactivity, making it difficult to separate HSV I from 
HSV2 using immunohistochemistry. Separation of VZ 
from HSV using monoclonal antibodies is not usually a 
problem in our experience. 
Differential Diagnosis. It can be difficult to distinguish 
the edge of an infarct from the periphery ofa necrotic HSV 
lesion. The most obvious distinction is that inclusion 
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Figure 69-22 Herpes simplex hepatitis (HSV). HSV and varicella-zoster hepatitis are characterized 
by large areas of coagulative-type necrosis. A. The center of the necrotic lesions contain neutrophils 
and nuclear debris, whereas more viable cells at the periphery (arrows) contain the inclusion bodies, 
when present. B, A higher magnification shows some multinucleated cells containing the characteristic 
Cowdry A type inclusions (arrow). 
bodies are present in HSV and VZ hepatitis and absent at 
the periphery of an infarct. However, unequivocal HSV 
inclusions may not be present; only cells with a smudged 
nuclear chromatin may be found. In such cases, it is our 
policy to overdiagnose HSV hepatitis in patients with a 
compatible clinical profile because, without the highly ef-
fective treatment, it can rapidly cause liver failure and 
death. 
Separation ofHSV-VZ hepatitis from CMV hepatitis is 
occasionally a problem. HSV is associated with large areas 
of coagulative-type necrosis, whereas, alone, CMV rarely 
causes confluent hepatocyte necrosis. In addition, CMV 
hepatitis may show nuclear and cytoplasmic inclusions, 
whereas the inclusions of HSV are exclusively nuclear. 
Epstein-Barr Virus 
EBV latently infects a majority of the general population. 
It often becomes active after liver transplantation when I 
to 2% of recipients experience persistent or recurrent EBV 
disease. This can eventually result in the development of 
posttransplant lymphoproliferative disorder (PTLD), 
which is a proliferation of B cells that sometimes acts like 
an aggressive lymphoma.261-268 As with the other oppor-
tunistic viruses, the incidence of disease is higher and the 
severity of the complications is worse in patients who were 
seronegative before transplantation but who received an 
allograft from a seropositive donor.261-268 
EBV is known to infect and lay dormant in B lympho-
cytes and some epithelial cells. In vitro. in the absence of 
T cell regulatory influences. infection ofB lymphocytes by 
EBV "immortalizes" the B cells, especially in the presence 
of immunosuppressive drugs.261-268In vivo. maintenance 
of viral latency is the productofimmune surveillance by T 
cells that keep viral replication and B cell proliferation in 
check. However. potent immunosuppressive therapy de-
presses immune surveillance and accounts for the various 
disease manifestations listed later. Recurrent or persistent 
disease can result in the emergence of oligoclonal or 
monoclonal B cell proliferations that sometimes act like 
aggressive lymphomas.267.268 It should be remembered 
that monoclonality alone does not necessarily mean that 
the lesion will behave autonomously and be free from im-
mune surveillance or need treatment with chemother-
apy.267. 268 A more detailed discussion of the pathophysiol-
ogy ofEBV in the allograft recipient is beyond the scope of 
this chapter. The interested reader is referred to several ex-
cellent reviews. 267. 268. 290-292 
Clinical Presentation. The systemic viral syndrome as-
sociated with EBV often resembles that seen with classic 
infectious mononucleosis. Fever, lymphadenitis, pharyn-
gitis. and jaundice261-268 are the typical findings, but 
atypical signs and symptoms in the form of jaw pain. 
arthralgia. joint space effusions. diarrhea. encephalitis. 
pneumonitis. and mediastinal lymphadenopathy and 
ascites can also be seen. Laboratory investigation usually 
shows elevation of the levels of hepatocellular liver en-
zymes and circulating atypical lymphocytes in the periph-
eral blood. Pancytopenia is noted on occasion.261-268 
Unresolved or recurrent EBV syndromes often culmi-
nate in the development of a PTLD.267. 268. 290-292 Al-
though PTLD can involve any site in the body, most com-
monly it affects the lymph nodes, hepatic allograft, and 
gastrointestinal tract. Signs and symptoms attributable to 
a mass lesion at the site of involvement are not uncom-
mon. Withdrawal or a dramatic reduction in immunosup-
pression with the addition of antiviral agents such as 
acyclovir is the first line of therapy regardless of 
the histopathological appearance or c10nality of the 
lesion.267. 268. 290-292 This maneuver is an attempt to re-
store immune regulation or surveillance. which, ifunsuc-
cessful. can be supplemented by conventional chemother-
apeutic treatment in some circumstances.267. 268. 290-292 
Histopathological Findings. EBV hepatitis usually 
shows portal and periportal mononuclear infiltrates of 
varying severity (Fig 69-23) composed of small and blas-
tic lymphocytes, some of which are atypical, admixed with 
plasmacytoid lymphocytes and plasma cells.261-266 Eosin-
ophils and neutrophils are much less common in the por-
tal tracts than in acute rejection. Bile duct damage can be 
seen. but the severity and prevalance of duct damage are 
less than would be expected for rejection on the basis of the 
severity of the portal infiltrate. 261-266 Subendothelial local-
ization of lymphocytes can be seen in the portal or central 
vems. 
The lobule typically shows features of a "reactive" or 
low-grade hepatitis taking the form of focal hepatocellular 
swelling, mild acidophilic necrosis of hepatocytes, and 
mild lobular disarray. 261-266 Regenerative activity, includ-
ing double-layered plates, pseudoacinar formation, and 
mitotic figures. is common. The sinusoids contain linearly 
aligned and focally aggregated mononuclear cells, which 
are cytologically similar to those seen in the portal triads. 
Occasional granulomatoid aggregates can also be seen. 
In the liver. PTLD manifests as map-like enlargement 
of portal triads because of sheets of monomorphic atypical 
immunoblastic cells (see Fig 69-23), which obscure the 
normal architectural landmarks. 261-266 Smaller aggregates 
composed of a similar cell population can be seen in the 
sinusoids. and on occasion. focal areas of necrosis are 
present. Cytologically, the infiltrate resembles an immu-
noblastic lymphoma. and there are usually many more 
cells with atypical cytological features. occasionally in-
cluding Reed-Sternberg-like cells. than seen in EBV hep-
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Figure 69-23 Epstein-Barr virus (EBV) hepatitis and 
posttransplantation Iymphoproliferative disorders. A. EBV hepatitis is 
characterized by a mononuclear portal infiltrate that sometimes is 
seen beneath the endothelium of the portal vein (arrow). There is also 
sinusoidal lymphocytosis (arrowheads) and mild lobular regenerative 
activity. B, Mistaken treatment of the patient whose biopsy is shown 
in A with increased immunosuppression resulted in the development 
of a posttransplantation Iymphoproliferative disorder seen here as 
maSSive expansion of the triads by a population of atypical 
mononuclear cells (inset) showing features of plasmacytic 
differentiation. C, Discontinuation of the immunosuppression (and 1 
day of cyclophosphamide treatment) in this patient resulted in 
resolution of the portal infiltrate and return of the normal architecture 
in 3 to 4 weeks, 
atitis. The diagnosis is confirmed by in situ hybridization 
for EBV RNA (EBER sequence). The reader is referred 
elsewhere for a detailed discussion of the extrahepatic 
manifestation of PTLD in lymph nodes and other 
tissues.267, 268, 290-292 
Differential Diagnosis. EBV hepatitis is most often con-
fused with acute rejection and acute and chronic type C 
and CMV hepatitis. 261-266 In addition to the clinicopatho-
logical profile. which is helpful in differentiating among 
these various syndromes, reliance is placed on adjuvant 
techniques to identify viral antigens and nucleic acids in 
the tissue. 261-266 Histopathologically, both hepatitis C and 
EBV can show sinusoidal lymphocytosis or a linear align-
ment of mononuclear cells in the sinusoids. However. the 
sinusoids contain cytologically atypical cells in EBV, 
whereas in HCV small. round. inactive-appearing lym-
phocytes are present in the sinusoids and portal 
tracts. 261- 266 
Separation ofEBV hepatitis or PTLD from acute rejec-
tion is also difficult at times. In acute rejection. the portal 
infiltrate typically is a mixed one. containing blastic and 
smaller lymphocytes. neutrophils. plasma cells. and often 
numerous eosinophils. In contrast. the portal infiltrate in 
EBV is less pleomorphic. consisting primarily of activated 
and immunoblastic mononuclear cells, many of which 
contain features of plasmacytic differentiation. Eosino-
phils and neutrophils are less common in EBV-related 
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disorders. Moreover, inflammatory infiltration and dam-
age of bile ducts are common in acute rejection, whereas 
in EBV -related disorders, the bile duct damage is relatively 
mild compared with the intense portal inflamma-
tion.261-266 
In the end, the diagnosis of EBV-related disorders is 
confirmed by in situ hybridization for the EBER RNA se-
Quence of EBV, a technique that has greatly assisted in 
the management of allograft recipients.26I • 262. 293 Wide-
spread availability of the EBER probe has led to a greater 
appreciation of the extent ofEBV infection in this popula-
tion, although the results have to be interpreted with cau-
tion.293 It is known that occasional cells containing the 
EBER sequence are not uncommon in the general popula-
tion and are found with increased frequency in an allograft 
recipient. The significance of occasional EBER-positive 
cells is open to debate.293 However, in our opinion, clus-
tering of such cells into aggregates or the presence of 
EBER-positive cells in tissues showing other histopatho-
logical features of EBV-associated disease (unpublished 
observation) points toward at least a transient defect in the 
ability to control viral replication and B cell proliferation. 
Caution with immunosuppression management in such 
patients is an appropriate course of action. 
Adenoviral HepatitiS 
~denoviral infe~i~n and disease after liver transplanta-
tIOn are largely limited to the pediatric population.294-296 
m~esumably most adults already have protective immu-
mty and, thus. are less susceptible. Viral subtypes I, 2, 
and 5 have been isolated from the lung, gastrointestinal 
tract, a~d liver in patients with fever, respiratory dis-
tress, diarrhea, and liver dysfunction.294-296 The onset 
of disease usually occurs between I and 10 weeks after 
transplantation, and biopsy histopathological study is 
used to ascertain tissue disease. Hepatitis is most often 
caused by subtype 5, but subtypes 2. II, and 16 have been 
aSSOCiated with hepatitis in the general population and 
could be expected to infect and cause disease in liver 
allografts. 294-296 
Histopathological Findings. Histopathologically, ade-
noviral hepatitis is distinctive, but some experience is re-
Quired to establish the diagnosis with certainty. Most 
characteristic are the "pox-like" granulomas, consisting 
almost entirely of macrophages, which are spread ran-
domly throughout the parenchyma, encompassing small 
groups of necrotic hepatocytes294- 296 (Fig 69-24). q~e 
nuclei of hepatocytes located near the edge of the necrotic 
zones or granulomas often contain the distinctive adeno-
viral inclusions (see Fig 69 - 24). They are characterized by 
a crowding of chromatin toward the nuclear membrane, 
imparting a muffin-shape appearance to the nucleus. Im-
munohistochemical staining is confirmatory. 
Differential Diagnosis. The histopathological differen-
tial diagnosis includes other causes of hepatic granu-
lomas, such as deep fungal or mycobacterial infections, 
that can be excluded by microbiological cultures of the 
biopsy and negative special stains for granuloma-causing 
organisms. CMV and HSV-VZ should also be distin-
guished from adenovirus. The granulomas associated with 
adenovirus consist almost entirely of macrophages and are 
much larger than the "microgranulomas" of CMV, and 
multinucleate giant cells are rare. In contrast, CMV causes 
cytomegaly and produces both eosinophilic intranuclear 
inclusions surrounded by a clear halo and basophilic or 
amphophilic small cytoplasmic inclusions. Adenovirus 
does not cause cytomegaly, the nucleus appears smudgy, 
and there are no cytoplasmic inclusions. The hepatocyte 
necrosis associated with adenovirus is generally less than 
that seen with HSV or VZ hepatitis. 
RECURRENT DISEASE 
Recurrence of the native liver disease in the allograft is un-
fortunately com mon unless the patient originally required 
~igure S~K-O4 Adenoviral hepatitis. A, Adenoviral hepatitis is histopathologically characterized by 
pox-like granulomas scattered throughout the lobules (surrounded by arrowheads). B. The 
granulomas consist almost entirely of macrophages. and cells near the granulomas contain "smudged" 
nudel (bottom arrow), whereas others contain the characteristic intranudear inclusions (top arrow). 
(Slides courtesy of R. Jaffe, Childrens Hospital. Pittsburgh, PA.) 
-transplantation for a liver-based metabolic disease. The 
latter disorders are generally cured after transplantation 
and include ai-antitrypsin deficiency, Wilson's disease, 
tyrosinemia, cholesterol low-density lipoprotein receptor 
deficiency, glycogenesis types I and 4, factors VlII and 
IX -deficient hemophilia, and familial amyloid polyneu-
ropathy.II, 297 Liver transplantation has provided valuable 
information about the pathogenesis of several of these dis-
orders,ll Reinvolvement of the liver by Gaucher's disease 
has been reported,298-JOO but in several cases, an overall 
improvement in patient health was better than expected 
from liver transplantation alone, U~I JOO Despite the associa-
tion of several different causative factors with giant cell 
hepatitis, recurrence of the disease, which is more com-
mon in children, has been reported in liver aliografts,301 
All of the virally induced cirrhoses, including hepatitis 
types B, C, and D, covered in detail previously, have been 
shown to recur after liver transplantation. In general, the 
rate of recurrent viral infection is high and the severity of 
posttransplant disease is often significant. Details as to the 
incidence and severity of recurrent viral hepatitis are given 
in the respective sections on those disorders. 
In contrast. the incidences of recurrent autoimmune 
disorders like primary biliary cirrhosis, "autoimmune" 
active chronic hepatitis, and sclerosing cholangitis 
at present appear to be lower than for viral hep-
atitis.123. 226, 269-271. 302-306 Moreover, recurrent autoim-
m une disease appears to be less severe than recurrent viral 
disease or the same autoimmune syndrome before 
transplantation. 123, 226. 269-271. 302-306 
Except for stage I (T I, NX, MX) hepatocellular carci-
nomas. other liver-based malignancies frequently recur 
after transplantation,307-309 as does the Budd-Chiari 
syndrome. II 
Recurrent PBC and autoimmune hepatitis have been 
the nonviral diseases studied in greatest de-
tail.71. 123.226.269-271.302-306 The recurrence rate for these 
two disorders varies from 0 to 90% after a follow-up period 
of I to 19 years after liver transplantation (Table 69 - 6). 
There are many possible reasons for these differences. in-
cluding pretransplant diagnosis. immunosuppressive 
management policies, length of posttransplant follow-up, 
operative techniques and other factors that would influ-
ence biliary tract physiology during or after transplan-
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tation, methods of ascertaining the diagnosis, and the 
influence of immunosuppression on the disease pro-
cess.7I, 123.226.269-271,302-306 
The diagnosis of recurrent PBC after liver transplanta-
tion is primarily based on pathognomonic histopathologi-
cal findings interpreted in the context of the clinical pro-
file. Re-elevation of antimitochondrial antibodies aft.!r 
transplantation is almost universal, although the titer may 
be lower.7l , 123,226,270-272,302-304 The diagnosis of autoim-
mune hepatitis is based on a combination of clinical, path-
ological, and serological findings once HCV has been 
excluded.270, Pl~I J06 In general, the histopathological man-
ifestations of recurrent PBC are identical to those seen in 
the native liver.71. 123,226.270-272, 302-304 Granulomatous 
duct damage producing breaks in the ductal basement 
membrane, or "florid duct lesions," is a "diagnostic" find-
ing, although lymphocytic duct infiltration and damage 
combined with a picture of an evolving biliary cirrhosis 
have also been seen (Fig 69 - 25). The lobule usually 
shows mild spotty necrosis, Kupffer cell hypertrophy, a 
slight increase in sinusoidal lymphocytes, and Kupffer cell 
granulomas. In the absence of pathognomonic findings, 
the diagnosis of recurrent primary biliary cirrhosis be-
comes less certain. 123 
Confirmation of the diagnosis of autoimmune hepatitis 
after transplantation is even more difficult than confirma-
tion of recurrent PBC. A chronic hepatitic histopathology, 
combined with negative RT-PCR for hepatitis C and no 
other evidence of viral hepatitis infection, in a patient who 
had autoimmune hepatitis with the appropriate autoanti-
bodies before transplantation points toward recurrent dis-
ease as a possibility. However, the possibility that a non-A. 
non-B. non-C. non-D viral hepatitis could cause a similar 
or identical histopathological profile cannot be excluded 
at this time. 
Data on cases of probable recurrence of primary scle-
rosing cholangitis are just beginning to emerge.70. 71 It has 
been tentatively identified from at least two institutions on 
the basis of an exhaustive search for other causes of biliary 
tract obstruction or stricturing.70. 71 However, this diag-
nosis, perhaps more than other recurrent diseases, is 
fraught with potential pitfalls. There are numerous insults 
that could potentially lead to the development of biliary 
tract obstruction or stricturing, including prolonged cold 
TABLE 69 - 6 Incidence 01 recurrent autoimmune liver diseases after liver transplantation 
Disease 
Primary biliary cirrhosis 
Autoimmune CAH 
Investigator 
Neuberger el a1 z" 
Polson et al JOz 
H u bscher et al 'lJ 
Balan et al 271 
Esquivel et a1~lg 
Demetris et alJ04 
Hart et alzz, 
Neuberger et al 270 
Sa nchez- U rdazpallO' 
Wright et al)()6 
NA - not applicable, original case n:poru: CAH - chronic active hepatitis. 
Time 01 
Follow-up, yr 
3-4 
> 1 
1-8 
2-6 
1-5 
> 1 
> 1 
Incidence 01 
Recurrent Disease, % 
NA 
90 
16 
2:8 
o 
o 
o 
NA 
o 
25 
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Figure 69-25 Recurrent primary biliary cint1osis. This needle biopsy 
was obtained in a 49-year-<>ld woman 1'12 years after she underwent 
liver transplantation lor primary biliary drmosis . Note the 
Iymphogranulomatoid portal infiltrate and bile duct damage (inset) , 
which was seen in only one or two of more than a dozen triads. Most 
all of the other triads were free from inflammation and bile duct damage. 
ischemia, arterial thrombosis or strictu ring, positive lym-
phocytotoxic crossmatch, and numerous operative or 
technical difficulties with the biliary anastomosis. There-
fore, when one observes histopathological findings sugges-
tive of recurrent PSC, one should try to exclude, as best as 
possible, the many other insults that could lead to similar, 
if not identical, histopathological findings. Harrison et apo 
noted that classic "fibro-obliterative duct lesions" were re-
stricted to liver allograft recipients who had PSC before 
transplantation . Even after an exhaustive search to rule 
out other causes of biliary strictures is complete, there will 
still remain cases of unexplained biliary strictures in pa-
tients whose original disease was PSc. In such cases a 
diagnosis of recurrence seems justified. 
Alcohol Injury 
End-stage alcoholic liver disease is a leading indication for 
liver transplantation at many centers. Despite rigorous 
pretransplant screening programs that attempt to identify 
patients who are likely to relapse after transplantation: re-
current alcoholism can be a cause of allograft dysfunctIOn. 
The exact incidence of recurrent alcohol use and abuse 
after transplantation in those who underwent transplanta-
tion for alcoholic liver disease is difficult to determine with 
certainty, but reported values range from 24 to 31 %310.311; 
despite this, there is a relatively small impact on the pa-
tient and allograft survival.310-312 Discussion of the patho-
physiological mechanisms of liver injury associated with 
alcohol abuse is beyond the scope of this chapter. 
Clinical Presentation. Problems with alcohol abuse re-
cidivism are usually detected because of elevation of liver 
injury test findings that are routinely obtained in liver 
transplant populations or inappropriate social behavior.71 
Isolated elevation of y-glutamyl transpeptidase in the ab-
sence of a concomitant rise in the alkaline phosphatase 
level can be seen, as in alcoholics from the general popula-
tion.71 Compliance with immunosuppression can also be 
a problem in these patients. 
Histopathological Findings. The histopathological find-
ings of alcohol abuse in a liver allograft are virtually iden-
tical to those seen in the general population. The most 
common is mixed steatosis involving centrilobular hepa-
tocytes, distributed in a distinctly zonal pattern (Fig 69-
26). So-called foamy degeneration of the hepatocytes is 
not uncommon.71 This can be accompanied on occasion 
by the presence of megamitochondria, Mallory's hyaline 
bodies, and the so-called alcoholic hepatitis lesion.29 Peri-
venular and subsinusoidal fibrosis. as well as increased 
iron deposition in the reticular endothelial cells and hepa-
tocytes. without steatosis can also be seen.71 
Figure 69-26 Recurrent alcohol abuse. A, A return to alcohol abuse is most often characterized 
histopathologically by centrilobular steatosis. which is often severe. S, Higher magnification shows that 
the steatosis is mixed (mictovesicular and macrovesicular). and occasionally, Mallory 's hyaline bodies 
(arrow) and acute "foamy" degeneration of hepatocytes are seen. Other causes of steatohepabtis 
should be eXcluded. 
In our experience, evolution toward cirrhosis in liver al-
lograft resulting from recurrent alcoholism appears in 
most cases to be a relatively slow process, although the 
data are too scarce to draw any conclusions at this point. In 
one patient who had particular difficulties with recurrent 
disease, bridging fibrosis developed within 5 years of 
the original transplantation procedure (unpublished 
observation). 
Differential Diagnosis. The differential diagnosis of re-
current alcoholism includes all of the disorders known to 
cause steatohepatitis, including obesity, poorly controlled 
diabetes, intestinal bypass surgery, malabsorption, hyper-
lipidemia, and toxicities of several drugs.29 In the allograft 
recipient, we have also seen similar changes in patients 
with a portal vein "steal" syndrome, in which the nu-
trient-rich portal blood bypasses the liver and elicits cen-
trilobular steatosis. Awareness of the original disease, de-
tailed clinical history, and blood alcohol levels can further 
strengthen a diagnosis of recurrent alcohol abuse that was 
suspected on the biopsy findings. Appropriate caution is 
urged so that a mistaken accusation is not made. 
LONG-TERM CHANGES 
Several studies7. 8. 71. 122. 123 have examined the structural 
integrity of the allograft and causes of dysfunction in recip-
ients who have survived from 1 to 19 yearsafterlivertrans-
plantation (Table 69 - 7). Even though the recipient pool, 
immunosuppressive management policies, and study de-
signs differed, the causes of allograft dysfunction were sim-
ilar. 7.8.71. 122. 123 Most remarkable was the relatively low 
incidence of acute and chronic rejection, which varied 
from 4 to 38%. Recurrence of the original disease, espe-
cially viral hepatitis, was a leading cause of dysfunction, 
and obstructive cholangiopathy also was surprisingly 
common. These observations support the contention that 
liver allografts are immunologically privileged.89 Pappo et 
aj11 particularly noted that awareness of the original dis-
ease. recent change in immunosuppressive management 
policies, a review of previous biopsies, the clinical profile, 
and the result of any therapeutic or diagnostic tests or in-
tervention should be incorporated with the biopsy find-
ings to correctly identify the cause of late allograft dys-
function. They also emphasized that interpretation of 
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liver allograft biopsies obtained from long-term survivors 
is often more difficult than interpretation of biopsies ob-
tained early after transplantation.71 
Clinical Presentation and Histopathological Find-
ings. Clinical presentation and histopathological find-
ings of acute and chronic rejection, viral hepatitis, ob-
structive cholangiopathy, and recurrent autoimmune 
diseases were discussed in the respective sections and are 
not repeated here. However, several histopathological 
changes in long-surviving allografts could not be attrib-
uted to a specific pathological process, albeit they were 
minimal deviations from normal. These included mild 
lymphocytic portal inflammation without significant duct 
damage or venulitis; portal arterial and arteriolar thicken-
ing and hyalinization; and subtle intralobular regenerative 
change, characterized by thickening of the plates and 
pseudorosette formation. This resulted in a vague nodu-
larity to many of the needle cores, although the findings 
were insufficient in most cases for an unequivocal diag-
nosis of nodular regenerative hyperplasia.71 The arterial 
changes were attributed to a combination of hypertension, 
diabetes, and injury.71 Because more centers may attempt 
drug withdrawal trials in the near future, protocol biopsies 
taken before stopping or lowering immunosuppression 
are encouraged.84• 130.313 
LIVER DISEASE ASSOCIATED WITH 
SYSTEMIC DISORDERS 
Septicemia 
Sepsis and intra-abdominal infections are frequent occur-
rences during the first I to 2 months after liver transplanta-
tion, and alone, they can be the main insult responsible 
for allograft dysfunction. The usual clinical signs and 
symptoms of infection, such as fever and chills. are accom-
panied by liver dysfunction primarily manifest as hyper-
bilirubinemia. The underlying mechanism of liver dys-
function in this setting may be related to endotoxemia and 
cytokine release from Kupffer cells. 
Histopathological Findings. Histopathological changes 
seen as a result of sepsis or endotoxemia are identical to 
those seen in the nonallograft liver. They include cholan-
TABLE 69- 7 Causes of late liver allograft dysfunction in recipients surviving 1-19 years after liver transplantation 
Variable 
Follow·up (yr) 
DiagnOSIs 
Nonspecific changes 
Obslruclive cholangiopathy 
Hepatitis 
Acu Ie and chronic rejection 
Other 
NA - not applicable. 
Starzl et al7 
1-7 
NA 
21% 
7% 
38% 
34% 
Nakhleh at al'22 Hubscher et al123 Pappo et al" 
3-4 1-8 5 -19 
32% 63% 24% 
7% 12% 6% 
34% 38% 35% 
15% 4% 15% 
13% 9% 20% 
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giolar proliferation with bile plugging, acute cho~angi­
olitis usually without cholangitis, hepatocanalicular 
cholestasis, and occasionally megakaryocytes within the 
sinusoids. 29- 31 Kupffer cells are often hypertrophic, and 
small clusters of neutrophils, unassociated with viral in-
clusions or cytomegalic cells, can be observed in the sinu-
soids. Another finding can be the presence of extramedul-
lary hematopoiesis.314 The histopathological differential 
diagnosis includes preservation injury, bile duct obstruc-
tion or stricturing, and humoral rejection.29- 31 
Differential Diagnosis. Blood or peritoneal fluid cul-
tures positive for bacteria or fungi confirm the diagnosis of 
sepsis or intra-alxiominal infection. The diagnosis of pres-
ervation injury is substantiated by review of the early post-
transplantation clinical course and previous biopsies, if 
available. The presence of preformed antidonor antibod-
ies, low platelet counts, hypocomplementemia, and IgO 
and C3 and C4 deposits in the liver biopsy favors a diag-
nosis of the humoral rejection. In some cases, it may be 
difficult if not impossible to differentiate between these 
possibilities on the basis of a single biopsy. The diagnosis 
becomes apparent only after reviewing serial biopsies dur-
ing evolution of the clinical syndrome. In general, dys-
function attributable to sepsis improves with appropriate 
antimicrobial therapy, whereas preservation injury spon-
taneously improves without specific therapeutic interven-
tion. In contrast, the histopathological changes and allo-
graft dysfunction usually worsen over a period of I to 2 
weeks, and acute (cellular) rejection appears if humoral 
rejection is the cause of dysfunction. 
DRUG AND TOXIC INJURY 
A discussion of the clinical presentation and histopatholo-
gical changes associated with adverse drug reactions is 
beyond the scope of this chapter. However, in general, the 
morphological manifestations induced by a particular 
agent in an allograft are likely to be the same as those de-
scribed for nonallograft livers. The exception may be 
drugs that induce an immunological response or cases in 
which altered self-antigens may precipitate or drive the re-
action. Such reactions could be blunted or even less com-
mon because of the potent immunosuppression. The use 
of azathioprine as an immunosuppressant in liver allograft 
recipient has been associated with the development of 
central lobular necrosis and central vein and sinusoidal fi-
brosis in the short term,315 and nodular regenerative hy-
perplasia has been seen with long-term use. 316 Because 
there are many insults that could potentially result in cen-
tral necrosis and fibrosis. appropriate caution is urged 
when the lesion is attributed to azathioprine. 
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